主要論文

2025年

1. Harigae H. XLSA breakthrough: gene therapy potential. Blood. 2025 Jan 2;145(1):5-6. doi: 10.1182/blood.2024026582. PMID: 39745690 No abstract available.
   https://pubmed.ncbi.nlm.nih.gov/39745690/
2. Kubo R, Onodera K, Onishi Y, Fukuhara N, Harigae H. Long-term remission following CAR-T therapy in a patient with transformed follicular lymphoma relapse after allogeneic stem cell transplantation. Ann Hematol. 2025 Jan;104(1):841-845. doi: 10.1007/s00277-024-06150-8. Epub 2024 Dec 30. PMID: 39738826　
   https://pubmed.ncbi.nlm.nih.gov/39738826/
3. Kosugi H, Fujisaki T, Iwasaki H, Shinagawa A, Iida H, Jo T, Kubonishi S, Morita Y, Nakashima Y, Onodera K, Suzuki K, Suzuki T, Tamai Y, Usuki K, Yokota A, Yonaga H, Hayakawa J, Midorikawa S, Nishio M, Suda M, Matsue K. A phase 2 clinical trial of luspatercept in non-transfusion-dependent patients with myelodysplastic syndromes. Int J Hematol. 2025 Jan;121(1):68-78. doi: 10.1007/s12185-024-03872-3. Epub 2024 Nov 21.　PMID: 39572468 Free PMC article. Clinical Trial.　
   https://pubmed.ncbi.nlm.nih.gov/39572468/
4. Shimada K, Yamaguchi M, Kuwatsuka Y, Matsue K, Sato K, Kusumoto S, Nagai H, Takizawa J, Fukuhara N, Nagafuji K, Miyazaki K, Ohtsuka E, Okamoto A, Sugita Y, Uchida T, Kayukawa S, Wake A, Ennishi D, Kondo Y, Meguro A, Kin Y, Minami Y, Hashimoto D, Nishiyama T, Shimada S, Masaki Y, Okamoto M, Atsuta Y, Kiyoi H, Suzuki R, Nakamura S, Kinoshita T. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): long-term results of a multicentre, single-arm, phase 2 trial. EClinicalMedicine. 2025 Jan 31;80:103078. doi: 10.1016/j.eclinm.2025.103078. eCollection 2025 Feb. PMID: 39968389 Free PMC article.
   https://pubmed.ncbi.nlm.nih.gov/39968389/
5. Okada Y, Tachi N, Shimazu Y, Murata M, Nishiwaki S, Onishi Y, Jinguji A, Uchida N, Tanaka M, Hasegawa Y, Ito A, Kako S, Nishida T, Onodera K, Sawa M, Nakamae H, Toyosaki M, Kanda Y, Onizuka M, Fukuda T, Ohbiki M, Atsuta Y, Arai Y, Tachibana T. Comparing de novo chronic myeloid leukemia in blastic phase with Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Cancer. 2025 Jan 1;131(1):e35627. doi: 10.1002/cncr.35627. Epub 2024 Nov 4. PMID: 39497254
   https://pubmed.ncbi.nlm.nih.gov/39497254/
6. Munakata W, Kumode T, Goto H, Fukuhara N, Shimoyama T, Takeuchi M, Kawakita T, Kubo K, Sawa M, Uchida T, Mishima Y, Ichii M, Hanaya M, Matsumoto A, Kuriki M, Seike T, Izutsu K, Ishizawa K. A phase II study of zandelisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma: ME-401-K02 study. Br J Haematol. 2025 Feb;206(2):541-550. doi: 10.1111/bjh.19994. Epub 2025 Jan 8. PMID: 39778876 Free PMC article. Clinical Trial.
   https://pubmed.ncbi.nlm.nih.gov/39778876/
7. Nato Y, Miyazaki K, Maruyama D, Takahashi H, Sunami K, Murakami S, Negoro E, Miyazawa Y, Choi I, Okada T, Takayama N, Tomita N, Momose S, Kaneda Y, Yoshida M, Gomyo H, Toyama K, Nishikori M, Saito A, Hiraga J, Masunari T, Takahashi N, Makiyama J, Suzuki T, Tsunemine H, Takizawa J, Kato T, Masaki Y, Fukuhara N, Okamoto M, Tawara I, Asano N, Ohshima K, Izutsu K, Kato K, Suzuki R, Yamaguchi M. Treatments and Outcomes of Newly Diagnosed CD5-Positive Diffuse Large B-Cell Lymphoma: A Multi-Institutional Observational Study. Hematol Oncol. 2025 Mar;43(2):e70047. doi: 10.1002/hon.70047.
   https://pubmed.ncbi.nlm.nih.gov/39937961/
8. Fujimoto A, Miyazaki K, Yakushijin K, Fujino T, Munakata W, Ejima Y, Maruyama D, Kubota N, Maeda T, Takizawa J, Hiramoto N, Takeuchi M, Sakai R, Fukuhara N, Taguchi S, Asano N, Yamaguchi M, Suzuki R. Improved prognosis of advanced-stage extranodal NK/T-cell lymphoma: results of the NKEA-Next study. Leukemia. 2025 Apr;39(4):909-916. doi: 10.1038/s41375-025-02527-4. Epub 2025 Feb 17. PMID: 39962328
   https://pubmed.ncbi.nlm.nih.gov/39962328/
9. Takahashi N, Harigae H. PAI-1, hematopoietic stem cell, and chronic myeloid leukemia. Biomed J. 2025 Apr 18:100854. doi: 10.1016/j.bj.2025.100854. Online ahead of print. PMID: 40254273 Free article.
   https://pubmed.ncbi.nlm.nih.gov/40254273/
10. Izutsu K, Fukuhara N. JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma-1. Follicular lymphoma (FL). Int J Hematol. 2025 May;121(5):577-585. doi: 10.1007/s12185-025-03922-4. Epub 2025 Feb 4. PMID: 39903435 No abstract available.
    https://pubmed.ncbi.nlm.nih.gov/39903435/
11. Fukuhara N, Yoshida I, Ishiguro T, Fujimoto K, Kuroda J, Uchida T, Yamamoto R, Ogawa Y, Hiramatsu Y, Ito T, Katagiri S, Nakazato T, Suzukawa K, Kinami K, Zhou M, Negoro E. PI3Kδ Inhibitor Parsaclisib in Japanese Patients With Relapsed or Refractory Follicular Lymphoma. Cancer Sci. 2025 Aug;116(8):2189-2197. doi: 10.1111/cas.70046. Epub 2025 May 14. PMID: 40365847 Free article.　
    https://pubmed.ncbi.nlm.nih.gov/40365847/
12. Izutsu K, Kumode T, Yuda J, Nagai H, Mishima Y, Suehiro Y, Yamamoto K, Fujisaki T, Ishitsuka K, Ishizawa K, Ikezoe T, Nishikori M, Akahane D, Fujita J, Jafarinasabian P, Soong D, D'Angelo Månsson B, Takahashi A, Favaro E, Fukuhara N. Efficacy and safety of epcoritamab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma: 3-year follow-up from the EPCORE NHL-3 trial. Int J Clin Oncol. 2025 Aug;30(8):1631-1640. doi: 10.1007/s10147-025-02788-0. Epub 2025 May 28.　PMID: 40434509　
    https://pubmed.ncbi.nlm.nih.gov/40434509/
13. Kobayashi T, Ishizawa K, Machida R, Sadachi R, Sasaki K, Kim H, Kataoka K, Munakata W, Fukuhara N, Nagai H; Lymphoma Study Group of the Japan Clinical Oncology Group. Obinutuzumab maintenance versus observation for patients with newly diagnosed high tumor burden follicular lymphoma who achieved complete metabolic response after obinutuzumab plus bendamustine induction therapy: a multicenter, randomized, phase III study (JCOG2008, MAIN study). Jpn J Clin Oncol. 2025 Jun 5;55(6):666-671. doi: 10.1093/jjco/hyaf038. PMID: 39997358　
    https://pubmed.ncbi.nlm.nih.gov/39997358/
14. Fukuhara N, Onizuka M, Kanda J, Asada N, Kato K, Ando K. Protocol for a multicentre, open-label, dose-escalation phase I/II study evaluating the tolerability, safety, efficacy and pharmacokinetics of repeated continuous intravenous PPMX-T003 in patients with aggressive natural killer cell leukaemia. BMJ Open. 2025 Jun 30;15(6):e098532. doi: 10.1136/bmjopen-2024-098532. PMID: 40588385 Free PMC article.　
    https://pubmed.ncbi.nlm.nih.gov/40588385/
15. Watanabe S, Kato H, Fujiwara T, Hatta S, Tomiya Y, Onodera K, Ichikawa S, Onishi Y, Yokoyama H, Fujishima F, Ichinohasama R, Harigae H, Fukuhara N. High FCGR2B Expression Can Identify Low-tumor-burden Follicular Lymphoma Patients Who Do Not Require Any Antilymphoma Therapy for a Long Term. Am J Surg Pathol. 2025 Jul 1;49(7):740-747. doi: 10.1097/PAS.0000000000002397. Epub 2025 Apr 7.　PMID: 40191878　
    https://pubmed.ncbi.nlm.nih.gov/40191878/
16. Fujiwara T, Harigae H. Molecular Insights into the Pathophysiology of Dysregulated Erythropoiesis: The Crucial Role of Iron Homeostasis. Mol Cell Biol. 2025 Sep 10:1-14. doi: 10.1080/10985549.2025.2553648. Online ahead of print.　PMID: 40928051
    https://pubmed.ncbi.nlm.nih.gov/40928051/
17. Ohmachi K, Kinoshita T, Maruyama D, Machida R, Sano Y, Yamauchi N, Fukuhara N, Uchida T, Yamamoto K, Miyazaki K, Tsukamoto N, Iida S, Yoshida I, Imaizumi Y, Suzuki Y, Yoshida S, Masaki Y, Murayama T, Yakushijin Y, Suehiro Y, Nosaka K, Dobashi N, Kuroda J, Takamatsu Y, Munakata W, Ando K, Ishizawa K, Ogura M, Yoshino T, Hotta T, Tsukasaki K, Tobinai K, Nagai H. Final results of JCOG0601 randomized trial of R-CHOP versus CHOP combined with dose-dense rituximab for diffuse large B-cell lymphoma. Jpn J Clin Oncol. 2025 Sep 2:hyaf134. doi: 10.1093/jjco/hyaf134. Online ahead of print. PMID: 40891733　
    https://pubmed.ncbi.nlm.nih.gov/40891733/
18. Goto H, Ito S, Kizaki M, Yamaguchi M, Fukuhara N, Kato K, Saito T, Terui Y, Soshin T, Satomi-Tsushita N, Honda H, Qian C, Izutsu K. Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma. Int J Clin Oncol. 2025 Sep 2. doi: 10.1007/s10147-025-02865-4. Online ahead of print. PMID: 40897939　
    https://pubmed.ncbi.nlm.nih.gov/40897939/
19. Mishima Y, Hashimoto D, Ichii M, Fukuhara N, Uchida T, Kato K, Omi A, Koroki Y, Shiga K, Maruyama D. Impact of best response to ibrutinib plus Bendamustine and rituximab on PFS in MCL: a secondary analysis of SHINE. Ann Hematol. 2025 Sep 13. doi: 10.1007/s00277-025-06569-7. Online ahead of print. PMID: 40940567
    https://pubmed.ncbi.nlm.nih.gov/40940567/
20. Izutsu K, Akahane D, Toubai T, Saito T, Mishima Y, Fujisaki T, Nishikori M, Kumode T, Suehiro Y, Ishitsuka K, Conlon R, Takahashi A, D'Angelo Månsson B, Favaro E, Fukuhara N. Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial. Leuk Lymphoma. 2025 Oct;66(10):1913-1921. doi: 10.1080/10428194.2025.2525983. Epub 2025 Jul 9.　PMID: 40632620　
    https://pubmed.ncbi.nlm.nih.gov/40632620/
21. Saburi M, Masunari T, Fukuhara N, Inagaki Y, Shimura A, Imoto N, Hasegawa Y, Hagihara M, Kobayashi N, Kumekawa H, Nakazawa H, Miyazaki K, Kawakita T, Isshiki T, Katsube A, Fujisawa S, Horigome Y, Koba Y, Jinnouchi F, Sekiguchi N. The Impact of Tirabrutinib Monotherapy for the Treatment of Bing-Neel Syndrome: A Multicenter Retrospective Study. Am J Hematol. 2025 Oct;100(10):1912-1915. doi: 10.1002/ajh.70029. Epub 2025 Aug 2. PMID: 40751704
    https://pubmed.ncbi.nlm.nih.gov/40751704/
22. Yokoyama H, Fukuhara N, Ando K, Iida H, Yamauchi T, Fukuhara S, Izutsu K, Tanoue Y, Yamamoto M, Tozaki H, Takahara E, Shoji S, Mizutani A, Morishita D, Oda RW, Miyake H, Yamamoto N. Phase I Study of Rogocekib in Patients with Relapsed or Refractory Hematologic Malignancies. Blood Adv. 2025 Oct 7:bloodadvances.2025017601. doi:10.1182/bloodadvances.2025017601. Online ahead of print.　PMID: 41056522
    https://pubmed.ncbi.nlm.nih.gov/41056522/
23. Zaimoku Y, Yamazaki H, Kanaya M, Hiramoto N, Ishiyama K, Takenaka K, Murata M, Uchida N, Doki N, Yamamoto R, Nishida T, Onodera K, Machida S, Kanda Y, Eto T, Kataoka K, Asada N, Itagaki M, Sakata-Yanagimoto M, Ishimaru F, Onizuka M, Ichinohe T, Atsuta Y, Onishi Y. Loss-Prone HLA Class I Alleles Inform Outcomes of Early Hematopoietic Cell Transplantation in Acquired Aplastic Anemia. Am J Hematol. 2025 Sep 5. doi: 10.1002/ajh.70054. Online ahead of print. PMID: 40910546　
    https://pubmed.ncbi.nlm.nih.gov/40910546/
24. Sakurai M, Kataoka K, Mizuno K, Mori T, Shirane S, Sakaguchi H, Mori T, Tanaka M, Tokunaga M, Onizuka M, Sakata-Yanagimoto M, Ishikawa J, Katayama Y, Ota S, Sawa M, Kato J, Hasegawa Y, Onodera K, Hattori N, Miyakoshi S, Takayama N, Nishida T, Kato K, Ishimaru F, Atsuta Y, Kanda J, Nakasone H, Terakura S. Risk Factors for and Impact of Pre-Engraftment Syndrome on Outcomes Following Single-Unit Cord Blood Transplantation in Adults. Am J Hematol. 2025 Sep 26. doi: 10.1002/ajh.70094. Online ahead of print. PMID: 41002003　
    https://pubmed.ncbi.nlm.nih.gov/41002003/

 

2024年

1. Hirai T, Asano K, Ito I, Miyazaki Y, Sugiura H, Agirbasli M, Kobayashi S, Kobayashi M, Shimada D, Natsume I, Kawasaki T, Ohba T, Tajiri S, Sakamaki F, Mineshita M, Takihara T, Sekiya K, Tomii K, Tomioka H, Kita H, Nishizaka Y, Fukui M, Miyata T, Harigae H. A randomized double-blind placebo-controlled trial of an inhibitor of plasminogen activator inhibitor-1 (TM5614) in mild to moderate COVID-19. Sci Rep. 2024 Jan 2;14(1):165. doi: 10.1038/s41598-023-50445-1. PMID: 38168544 Free PMC article. Clinical Trial.
   https://pubmed.ncbi.nlm.nih.gov/38168544/
2. Goto H, Ito S, Kizaki M, Yamaguchi M, Fukuhara N, Kato K, Saito T, Terui Y, Okubo S, Soshin T, Zeng J, Honda H, Badawi M, Ross JA, Izutsu K. Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma. Int J Clin Oncol. 2024 Feb;29(2):232-240. doi: 10.1007/s10147-023-02443-6. Epub 2023 Dec 29.PMID: 38157190　 Free PMC article. 　Clinical Trial.
   https://pubmed.ncbi.nlm.nih.gov/38157190/
3. Makita S, Ota S, Mishima Y, Usuki K, Ennishi D, Yanada M, Fukuhara N, Yamamoto R, Takamine A, Nohara G, Izutsu K. Japanese phase Ib study of the oral PI3K-δ and -γ inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. Int J Hematol. 2024 Feb;119(2):156-163. doi: 10.1007/s12185-023-03689-6. Epub 2023 Dec 27.　PMID: 38150138 　Clinical Trial.　
   https://pubmed.ncbi.nlm.nih.gov/38150138/
4. Onishi Y. Aplastic anemia: history and recent developments in diagnosis and treatment. Int J Hematol. 2024 Mar;119(3):217-219. doi: 10.1007/s12185-024-03715-1. Epub 2024 Feb 4.PMID: 38310173　
   https://pubmed.ncbi.nlm.nih.gov/38310173/
5. Imahashi N, Kurita N, Konuma T, Takahashi S, Nishida T, Tanaka M, Nakamae H, Kawakita T, Ota S, Doki N, Onishi Y, Sawa M, Ozeki K, Hiramoto N, Onizuka M, Ishimaru F, Ichinohe T, Atsuta Y, Kanda J. Effect of Conditioning Regimens and Graft-versus-Host Disease Prophylaxis on the Outcomes of Umbilical Cord Blood Transplantation Performed with Cyclophosphamide/Total Body Irradiation-Based Regimens. Transplant Cell Ther. 2024 Mar;30(3):318.e1-318.e11. doi: 10.1016/j.jtct.2023.12.004. Epub 2023 Dec 9.PMID: 38081416
   https://pubmed.ncbi.nlm.nih.gov/38081416/
6. Onozawa M, Kusumoto S, Najima Y, Hashimoto H, Okada K, Tamaki M, Tanaka M, Sato T, Takahashi T, Hatano K, Onodera K, Moriuchi Y, Yakushijin K, Kanda J, Nagafuji K, Ogata M, Nakano N, Tamori A, Mizokami M. Outcomes of Cessation of Nucleos(t)ide Analog Administration on Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Retrospective Study. Transplant Cell Ther. 2024 Mar;30(3):330.e1-330.e8. doi: 10.1016/j.jtct.2024.01.059. Epub 2024 Jan 17.　PMID: 38242442.
   https://pubmed.ncbi.nlm.nih.gov/38242442/
7. Mitani K, Lee JW, Jang JH, Tomiyama Y, Miyazaki K, Nagafuji K, Usuki K, Uoshima N, Fujisaki T, Kosugi H, Matsumura I, Sasaki K, Kizaki M, Sawa M, Hidaka M, Kobayashi N, Ichikawa S, Yonemura Y, Murotani K, Shimizu M, Matsuda A, Ozawa K, Nakao S. Long-term efficacy and safety of romiplostim in refractory aplastic anemia: follow-up of a phase 2/3 study. Blood Adv. 2024 Mar 26;8(6):1415-1419. doi: 10.1182/bloodadvances.2023010959. PMID: 38134300 Free PMC article. Clinical Trial. No abstract available.
   https://pubmed.ncbi.nlm.nih.gov/38134300/
8. Dreyling M, Fowler NH, Dickinson M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Pérez-Simón JA, Chen AI, Nastoupil LJ, von Tresckow B, María Ferreri AJ, Teshima T, Patten PEM, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Malladi R, Paule I, Zia A, Awasthi R, Han X, Germano D, O'Donovan D, Ramos R, Maier HJ, Masood A, Thieblemont C, Schuster SJ. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update. Blood. 2024 Apr 25;143(17):1713-1725. doi: 10.1182/blood.2023021567. PMID: 38194692
   https://pubmed.ncbi.nlm.nih.gov/38194692/
9. Sakurai K, Saito K, Hatta S, Katsuoka Y, Meguro K, Yokoyama H, Izumi T. Successful haploidentical hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria with severe pancytopenia developed after long-term aplastic anemia treatment. Clin Case Rep. 2024 Apr 26;12(5):e8832. doi: 10.1002/ccr3.8832. eCollection 2024 May. PMID: 38681032 　
   https://pubmed.ncbi.nlm.nih.gov/38681032/
10. Izutsu K, Ubukawa K, Morishita T, Onishi Y, Ishizawa K, Fujii Y, Kimura N, Yokochi M, Naoe T. Glasdegib with intensive/nonintensive chemotherapy in Japanese patients with untreated acute myeloid leukemia or high-risk myelodysplastic syndromes. Cancer Sci. 2024 Apr;115(4):1250-1260. doi: 10.1111/cas.16054. Epub 2024 Feb 7. PMID: 38327103 Free PMC article. Clinical Trial.
    https://pubmed.ncbi.nlm.nih.gov/38327103/
11. Nakaya Y, Nakamae H, Nishikubo M, Kondo E, Fukuda T, Hiramoto N, Mori Y, Nagafuji K, Eto T, Onishi Y, Uchida N, Ishikawa J, Matsuoka KI, Yui S, Takase K, Kawakita T, Kanda J, Ichinohe T, Atsuta Y, Kako S. Peripheral blood stem cell transplantation using HLA-haploidentical donor with post-transplant cyclophosphamide versus HLA-matched sibling donor for lymphoma. Bone Marrow Transplant. 2024 May;59(5):630-636. doi: 10.1038/s41409-024-02229-y. Epub 2024 Feb 14.　PMID: 38355911
    https://pubmed.ncbi.nlm.nih.gov/38355911/
12. Yamamoto R, Hiramoto N, Fujimoto A, Yamazaki H, Mori T, Uchida N, Doki N, Kato J, Nishikubo M, Kako S, Nishida T, Ota S, Onizuka M, Eto T, Onodera K, Ikegame K, Matsuoka KI, Kanda Y, Fukuda T, Atsuta Y, Onishi Y. Impact of antithymocyte globulin usage and risk stratification for posttransplant lymphoproliferative disorders in aplastic anemia patients after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2024 May;59(5):688-691. doi: 10.1038/s41409-024-02234-1. Epub 2024 Feb 10.PMID: 38341498.
    https://pubmed.ncbi.nlm.nih.gov/38341498/
13. Nakamura Y, Zaimoku Y, Yamaguchi H, Yamazaki H, Kanaya M, Uchida N, Doki N, Sakurai M, Hiramoto N, Kako S, Onizuka M, Onodera K, Maruyama Y, Ohigashi H, Nishida T, Yoshihara S, Matsuoka KI, Eto T, Kanda Y, Fukuda T, Atsuta Y, Onishi Y. Significance of absolute neutrophil count before allogeneic hematopoietic stem cell transplantation in adult patients with aplastic anemia. Ann Hematol. 2024 Aug;103(8):3121-3133. doi: 10.1007/s00277-024-05800-1. Epub 2024 May 16.
    https://pubmed.ncbi.nlm.nih.gov/38750374/
14. Teshima T, Onishi Y, Kato K, Taniguchi S, Miyamura K, Fukushima K, Kato J, Ishikawa T, Doki N, Nakamae H, Maeda Y, Inamoto Y, Okada M, Maki A, Shimada F, Tajima T, Wroclawska M, Zeiser R, Onizuka M. Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial. Int J Hematol. 2024 Jul;120(1):106-116. doi: 10.1007/s12185-024-03772-6. Epub 2024 May 25.
    https://pubmed.ncbi.nlm.nih.gov/38796666/
15. Fujiwara T, Harigae H. Pyridoxine: beyond a cofactor of ALAS. Blood. 2024 Sep 26;144(13):1358-1359. doi: 10.1182/blood.2024025575.
    https://pubmed.ncbi.nlm.nih.gov/39325482/
16. Dupuis J, Bachy E, Morschhauser F, Cartron G, Fukuhara N, Daguindau N, Casasnovas RO, Snauwaert S, Gressin R, Fox CP, d'Amore FA, Staber PB, Tournilhac O, Bouabdallah K, Thieblemont C, André M, Rai S, Ennishi D, Gkasiamis A, Nishio M, Fornecker LM, Delfau-Larue MH, Sako N, Mule S, de Leval L, Gaulard P, Tsukasaki K, Lemonnier F. Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study. Lancet Haematol. 2024 Jun;11(6):e406-e414. doi: 10.1016/S2352-3026(24)00102-9. PMID: 38796193 Clinical Trial.
    https://pubmed.ncbi.nlm.nih.gov/38796193/
17. Nakamura Y, Zaimoku Y, Yamaguchi H, Yamazaki H, Kanaya M, Uchida N, Doki N, Sakurai M, Hiramoto N, Kako S, Onizuka M, Onodera K, Maruyama Y, Ohigashi H, Nishida T, Yoshihara S, Matsuoka KI, Eto T, Kanda Y, Fukuda T, Atsuta Y, Onishi Y. Significance of absolute neutrophil count before allogeneic hematopoietic stem cell transplantation in adult patients with aplastic anemia. Ann Hematol. 2024 Aug;103(8):3121-3133. doi: 10.1007/s00277-024-05800-1. Epub 2024 May 16.　PMID: 38750374
    https://pubmed.ncbi.nlm.nih.gov/38750374/
18. Yamaguchi M, Fukuhara N, Takizawa J, Ishitsuka K, Yokohama A, Miyazaki K, Nato Y, Ichikawa S, Mitobe M, Shima K, Miyazawa Y, Izutsu K, Suzuki R, Nagai H, Nakamura N. Alemtuzumab monotherapy for T-cell prolymphocytic leukemia: an observational study in Japan. J Clin Exp Hematop. 2024 Sep 28;64(3):216-222. doi: 10.3960/jslrt.24028. Epub 2024 Jul 2. PMID: 38960696 Free PMC article.
    https://pubmed.ncbi.nlm.nih.gov/38960696/
19. Oyake T, Maeta T, Takahata T, Tamai Y, Kameoka Y, Takahashi N, Miyairi Y, Murai K, Shimosegawa K, Yoshida K, Inokura K, Fukuhara N, Harigae H, Sato R, Ishizawa K, Tajima K, Saitou S, Fukatsu M, Ikezoe T, Tsunoda S, Mita M, Mori J, Kowata S, Ito S. Real-world retrospective analysis of immune checkpoint inhibitor therapy for relapsed or refractory Hodgkin's lymphoma. J Clin Exp Hematop. 2024 Sep 28;64(3):191-202. doi: 10.3960/jslrt.24021. Epub 2024 Jul 31. PMID: 39085129 Free PMC article.
    https://pubmed.ncbi.nlm.nih.gov/39085129/
20. Kusumoto S, Munakata W, Machida R, Terauchi T, Onaya H, Oguchi M, Iida S, Nosaka K, Suzuki Y, Harada Y, Miyazaki K, Maruta M, Fukuhara N, Toubai T, Kubota N, Ohmachi K, Saito T, Rai S, Mizuno I, Fukuhara S, Takeuchi M, Tateishi U, Maruyama D, Tsukasaki K, Nagai H. Interim PET-guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced-stage classic Hodgkin lymphoma (JCOG1305). Cancer Sci. 2024 Oct;115(10):3384-3393. doi: 10.1111/cas.16281. Epub 2024 Jul 22. PMID: 39034771 Free PMC article.
    https://pubmed.ncbi.nlm.nih.gov/39034771/
21. Kawajiri A, Li J, Koinuma K, Yang Z, Yoon HJ, Yi J, Nagashima H, Ishii M, Gao F, Sato K, Tayama S, Harigae H, Iwakura Y, Ishii N, Sher A, Ishigaki K, Zhu J, Kim KS, Kawabe T. Naturally arising memory-phenotype CD4+ T lymphocytes contain an undifferentiated population that can generate TH1, TH17, and Treg cells. Sci Adv. 2024 Dec 6;10(49):eadq6618. doi: 10.1126/sciadv.adq6618. Epub 2024 Dec 4. PMID: 39630890 Free PMC article
    https://pubmed.ncbi.nlm.nih.gov/39630890/

 

2023年

1. Fukuhara N, Maruyama D, Hatake K, Nagai H, Makita S, Kamezaki K, Uchida T, Kusumoto S, Kuroda J, Iriyama C, Yanada M, Tsukamoto N, Suehiro Y, Minami H, Garcia-Vargas J, Childs BH, Yasuda M, Masuda S, Tsujino T, Terao Y, Tobinai K. Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study. Int J Hematol. 2023 Jan;117(1):100-109. doi: 10.1007/s12185-022-03455-0. Epub 2022 Sep 29. PMID: 36175779 Free PMC article. Clinical Trial.
   https://pubmed.ncbi.nlm.nih.gov/36175779/
2. Fukuhara N, Kato K, Goto H, Takeshi T, Kawaguchi M, Tokushige K, Akashi K, Teshima T, Harigae H, Schuster SJ, Thieblemont C, Dreyling M, Fowler N. Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial. Int J Hematol. 2023 Feb;117(2):251-259. doi: 10.1007/s12185-022-03481-y. Epub 2022 Nov 21.　PMID: 36404384 Free PMC article. Clinical Trial.
   https://pubmed.ncbi.nlm.nih.gov/36404384/
3. Takahashi N, Kameoka Y, Onizuka M, Onishi Y, Takahashi F, Dan T, Miyata T, Ando K, Harigae H. Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor. Cancer Med. 2023 Feb;12(4):4250-4258. doi: 10.1002/cam4.5292. Epub 2022 Sep 23. PMID: 36151699 Free PMC article.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC9972105/
4. Souri M, Osaki T, Shimura Y, Ichikawa S, Mori M, Ogawa Y, Ichinose A. Identification of non-neutralizing anti-factor X autoantibodies in three Japanese cases of autoimmune acquired factor X deficiency. Haemophilia. 2023 Mar;29(2):555-563. doi: 10.1111/hae.14711. Epub 2022 Dec 8. PMID: 36478471
   https://pubmed.ncbi.nlm.nih.gov/36478471/
5. Miyakawa Y, Imada K, Ichikawa S, Uchiyama H, Ueda Y, Yonezawa A, Fujitani S, Ogawa Y, Matsushita T, Asakura H, Nishio K, Suzuki K, Hashimoto Y, Murakami H, Tahara S, Tanaka T, Matsumoto M. The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study. Int J Hematol. 2023 Mar;117(3):366-377. doi: 10.1007/s12185-022-03495-6. Epub 2022 Nov 24. PMID: 36427162 Free PMC article. Clinical Trial.
   https://pubmed.ncbi.nlm.nih.gov/36427162/
6. Nakamura Y, Mori T, Kako S, Yamazaki H, Kanda Y, Uchida N, Tanaka M, Nawa Y, Fukuda T, Ichinohe T, Atsuta Y, Onishi Y. Outcome of peripheral blood stem cell transplantation from HLA-identical sibling donors for adult patients with aplastic anemia. Int J Hematol. 2023 Mar;117(3):356-365. doi: 10.1007/s12185-022-03487-6. Epub 2022 Nov 15.　PMID: 36378405
   https://pubmed.ncbi.nlm.nih.gov/36378405/
7. Munakata W, Ando K, Yokoyama M, Fukuhara N, Yamamoto K, Fukuhara S, Ohmachi K, Mishima Y, Ichikawa S, Ogiya D, Aoi A, Hatsumichi M, Tobinai K. Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies. Int J Hematol. 2023 Apr;117(4):553-562. doi: 10.1007/s12185-022-03514-6. Epub 2022 Dec 28.　PMID: 36576659 Free PMC article. Clinical Trial.　
   https://pubmed.ncbi.nlm.nih.gov/36576659/
8. Onishi Y, Furukawa E, Kamata M, Fukatsu M, Kameoka Y, Hatta S, Hamada H, Oyake T, Kai T, Sukegawa M, Nakajima S, Yanagiya R, Yamaguchi K, Takahashi T, Harazaki Y, Izumi T, Murai K, Ito S, Ikezoe T, Ishizawa K, Takahashi N, Harigae H. Outcomes of adult patients with early T-cell precursor (ETP) acute lymphoblastic leukemia/lymphoma (ALL) and non-ETP T-ALL. Int J Hematol. 2023 May;117(5):738-747. doi: 10.1007/s12185-023-03546-6. Epub 2023 Feb 9. PMID: 36757523
   https://pubmed.ncbi.nlm.nih.gov/36757523/
9. Miyazaki K, Sakai R, Iwaki N, Yamamoto G, Murayama K, Nishikori M, Sunami K, Yoshida I, Yano H, Takahashi N, Okamoto A, Munemoto S, Sawazaki A, Suehiro Y, Fukuhara N, Wake A, Arai A, Masaki Y, Toyama K, Yokoyama A, Tsunemine H, Hasegawa Y, Matsumoto K, Yamada T, Nishimura Y, Tamaru S, Asano N, Miyawaki K, Izutsu K, Kinoshita T, Suzuki R, Ohshima K, Kato K, Katayama N, Yamaguchi M. Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL. Cancer Sci. 2023 Jun;114(6):2689-2691. doi: 10.1111/cas.15784. Epub 2023 Mar 16. PMID: 36929591　 Free PMC article. Clinical Trial.
   https://pubmed.ncbi.nlm.nih.gov/36929591/
10. Goto H, Kitawaki T, Fujii N, Kato K, Onishi Y, Fukuhara N, Yamauchi T, Toratani K, Kobayashi H, Yoshida S, Shimo M, Onodera K, Senjo H, Onozawa M, Hirata K, Yokota I, Teshima T. Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan. Int J Clin Oncol. 2023 Jun;28(6):816-826. doi: 10.1007/s10147-023-02334-w. Epub 2023 Apr 18.PMID: 37071252
    https://pubmed.ncbi.nlm.nih.gov/37071252/
11. Kameda K, Yanagiya R, Miyatake Y, Carreras J, Higuchi H, Murayama H, Ishida T, Ito A, Iida S, Fukuhara N, Harigae H, Fujioka Y, Takahashi N, Wada H, Ishida F, Nakazawa H, Ishihara R, Murakami Y, Tagawa H, Matsuura T, Nakagawa S, Iwabuchi S, Hashimoto S, Imadome KI, Nakamura N, Ishizawa K, Kanda Y, Ando K, Kotani A. The hepatic niche leads to aggressive natural killer cell leukemia proliferation through the transferrin-transferrin receptor 1 axis. Blood. 2023 Jul 27;142(4):352-364. doi: 10.1182/blood.2022018597. PMID: 37146246
    https://pubmed.ncbi.nlm.nih.gov/37146246/
12. Ogura M, Yamamoto K, Morishima Y, Wakabayashi M, Tobinai K, Ando K, Uike N, Kurosawa M, Gomyo H, Taniwaki M, Nosaka K, Tsukamoto N, Shimoyama T, Fukuhara N, Yakushijin Y, Ohnishi K, Miyazaki K, Kameoka Y, Takayama N, Hanamura I, Kobayashi H, Usuki K, Kobayashi N, Ohyashiki K, Utsumi T, Kumagai K, Maruyama D, Ohmachi K, Matsuno Y, Nakamura S, Hotta T, Tsukasaki K, Nagai H. Long-term follow-up after R-High CHOP/CHASER/LEED with Auto-PBSCT in untreated mantle cell lymphoma-Final analysis of JCOG0406. Cancer Sci. 2023 Aug;114(8):3461-3465. doi: 10.1111/cas.15849. Epub 2023 May 26. PMID: 37232264 　Free PMC article.
    https://pubmed.ncbi.nlm.nih.gov/37232264/
13. Röth A, Ichikawa S, Ito Y, Kim JS, Nagy Z, Obara N, Panse J, Schrezenmeier H, Sica S, Soret J, Usuki K, Yoon SS, Balachandran N, Buri M, Lundberg P, Patel H, Shinomiya K, Sostelly A, Nishimura JI. Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long-term results from the phase I/II COMPOSER trial. Eur J Haematol. 2023 Aug;111(2):300-310. doi: 10.1111/ejh.14011. Epub 2023 Jun 15. PMID: 37321625 Clinical Trial.
    https://onlinelibrary.wiley.com/doi/10.1111/ejh.14011
14. Kim WS, Fukuhara N, Yoon DH, Yamamoto K, Uchida T, Negoro E, Izutsu K, Terui Y, Nakajima H, Ando K, Suehiro Y, Kang HJ, Ko PS, Nagahama F, Sonehara Y, Nagai H, Tien HF, Kwong YL, Tobinai K. Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study Blood Adv. 2023 Sep 12;7(17):4903-4912. doi: 10.1182/bloodadvances.2022008615. PMID: 36661315 Clinical Trial.
    https://pubmed.ncbi.nlm.nih.gov/36661315/
15. Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, Rodrίguez-Otero P, Martinez-Lopez J, Koehne G, Touzeau C, Jethava Y, Quach H, Depaus J, Yokoyama H, Gabayan AE, Stevens DA, Nooka AK, Manier S, Raje N, Iida S, Raab MS, Searle E, Leip E, Sullivan ST, Conte U, Elmeliegy M, Czibere A, Viqueira A, Mohty M. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023 Sep;29(9):2259-2267. doi: 10.1038/s41591-023-02528-9. Epub 2023 Aug 15. PMID: 37582952 　Free PMC article. Clinical Trial.
    https://pubmed.ncbi.nlm.nih.gov/37582952/
16. Arakawa Y, Narita Y, Nagane M, Mishima K, Terui Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N, Aoi A, Nishikawa R. Karnofsky Performance Status and quality of life in patients with relapsed or refractory primary CNS lymphoma from a phase I/II study of tirabrutinib. Neurooncol Adv. 2023 Sep 14;5(1):vdad109. doi: 10.1093/noajnl/vdad109. eCollection 2023 Jan-Dec. PMID: 37744697 　Free PMC article.
    https://pubmed.ncbi.nlm.nih.gov/37744697/
17. Uchibori Y, Onodera K, Onishi Y, Komatsu H, Takenaka K, Narumi Y, Watanabe T, Nakamura H, Sakurai K, Hashimoto K, Inokura K, Ichikawa S, Fukuhara N, Yokoyama H, Harigae H. Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes with Donor-Specific Anti-HLA Antibodies against HLA-DP. Tohoku J Exp Med. 2023 Oct 17;261(2):123-127. doi: 10.1620/tjem.2023.J063. Epub 2023 Aug 10. PMID: 37558420　 Free article.
    https://pubmed.ncbi.nlm.nih.gov/37558420/
18. Izutsu K, Yamamoto K, Kato K, Ishikawa T, Fukuhara N, Terui Y, Choi I, Okubo S, Ogawa N, Sakai M, Nishimura Y, Chyla B, Sun Y, Maruyama D. Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax. Int J Hematol. 2023 Oct;118(4):526-528. doi: 10.1007/s12185-023-03646-3. Epub 2023 Aug 15. PMID: 37581752 　Free PMC article.　 No abstract available.
    https://pubmed.ncbi.nlm.nih.gov/37581752/
19. Fuji S, Hakoda A, Kanda J, Fukuda T, Doki N, Katayama Y, Uchida N, Ozawa Y, Kanda Y, Tanaka M, Kataoka K, Ara T, Sawa M, Onizuka M, Onishi Y, Kimura T, Ichinohe T, Atsuta Y, Shintani A, Morishima S. Impact of HLA disparity on overall mortality risk in patients with extensive chronic GVHD: The HLA Working Group of Japanese Society for Transplantation and Cellular Therapy. Bone Marrow Transplant. 2023 Nov;58(11):1257-1259. doi: 10.1038/s41409-023-02076-3. Epub 2023 Aug 7.PMID: 37550450 No abstract available.
    https://pubmed.ncbi.nlm.nih.gov/37550450/
20. Onishi Y, Mori T, Yamazaki H, Hiramoto N, Zaimoku Y, Kanaya M, Matsue K, Onizuka M, Aotsuka N, Uchida N, Onodera K, Kanda J, Nakamae H, Yamamoto R, Kuriyama T, Kimura T, Ichinohe T, Atsuta Y; Adult Aplastic Anemia Working Group of the Japanese Society for Transplantation and Cellular Therapy. Comparison of Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus Umbilical Cord Blood Transplantation in Adult Patients with Aplastic Anemia. Transplant Cell Ther. 2023 Dec;29(12):766.e1-766.e8. doi: 10.1016/j.jtct.2023.09.009. Epub 2023 Sep 18.　PMID: 37730121.
    https://pubmed.ncbi.nlm.nih.gov/37730121/
21. Izutsu K, Kumode T, Yuda J, Nagai H, Mishima Y, Suehiro Y, Yamamoto K, Fujisaki T, Ishitsuka K, Ishizawa K, Ikezoe T, Nishikori M, Akahane D, Fujita J, Dinh M, Soong D, Noguchi H, Buchbjerg JK, Favaro E, Fukuhara N. Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma. Cancer Sci. 2023 Dec;114(12):4643-4653. doi: 10.1111/cas.15996. Epub 2023 Nov 3. PMID: 37921363 Free PMC article.
    https://pubmed.ncbi.nlm.nih.gov/37921363/

 

2022年

1. Yamamoto K, Shinagawa A, DiNardo D　C.,Pratz W K, Ishizawa K, Miyamoto　T ,Komatsu N, Nakashima Y, Yoshida C, Fukuhara N, Usuki K, Yamauchi T, Asada N, Asou　N, Choi I, Miyazaki Y, Honda H, Okubo　S, Kurokawa M, Zhou Y, Zha J, Potluri J, Matsumura　I. Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. Jpn J Clin Oncol. 2022 Jan 3;52(1):29-38. doi: 10.1093/jjco/hyab170.
   https://pubmed.ncbi.nlm.nih.gov/34739075/
2. Hiramoto N, Yamazaki H, Nakamura Y, Uchida N, Murata M, Kondo T, Yoshioka S, Eto T, Nishikawa A, Kimura T, Ichinohe T, Atsuta Y, Onishi Y, Suzuki R, Mori T; Adult Aplastic Anemia Working Group of the Japanese Society for Hematopoietic Cell Transplantation. Total body irradiation-containing conditioning regimens without antithymocyte globulin in adults with aplastic anemia undergoing umbilical cord blood transplantation. Ann Hematol. 2022 Jan;101(1):165-175. doi: 10.1007/s00277-021-04664-z. Epub 2021 Sep 21.　PMID: 34546409
   https://pubmed.ncbi.nlm.nih.gov/34546409/
3. Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Pérez-Simón JA, Chen AI, Nastoupil LJ, von Tresckow B, Ferreri AJM, Teshima T, Patten PEM, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Malladi R, Zia A, Awasthi R, Masood A, Anak O, Schuster SJ, Thieblemont C. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022 Feb;28(2):325-332. doi: 10.1038/s41591-021-01622-0. Epub 2021 Dec 17.
   https://pubmed.ncbi.nlm.nih.gov/34921238/
4. Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong YL, Kersten MJ, Minnema MC, Holte H, Chan EHL, Martinez-Lopez J, Müller AMS, Maziarz RT, McGuirk JP, Bachy E, Le Gouill S, Dreyling M, Harigae H, Bond D, Andreadis C, McSweeney P, Kharfan-Dabaja M, Newsome S, Degtyarev E, Awasthi R, Del Corral C, Andreola G, Masood A, Schuster SJ, Jäger U, Borchmann P, Westin JR. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med. 2022 Feb 17;386(7):629-639. doi: 10.1056/NEJMoa2116596. Epub 2021 Dec 14.
   https://pubmed.ncbi.nlm.nih.gov/34904798/
5. Miyazaki K, Suzuki R, Oguchi M, Taguchi S, Amaki J, Maeda T, Kubota N, Maruyama D, Terui Y, Sekiguchi N, Takizawa J, Tsukamoto H, Murayama T, Ando T, Matsuoka H, Hasegawa M, Wada H, Sakai R, Kameoka Y, Tsukamoto N, Choi I, Masaki Y, Shimada K, Fukuhara N, Utsumi T, Uoshima N, Kagami Y, Asano N, Ejima Y, Katayama N, Yamaguchi M. Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma. Hematol Oncol. 2022 Oct;40(4):667-677. doi: 10.1002/hon.2977. Epub 2022 Mar 2.
   https://pubmed.ncbi.nlm.nih.gov/35142384/
6. Al-Samkari H, Galactéros F, Glenthøj A, Rothman JA, Andres O, Grace RF, Morado-Arias M, Layton DM, Onodera K, Verhovsek M, Barcellini W, Chonat S, Judge MP, Zagadailov E, Xu R, Hawkins P, Beynon V, Gheuens S, van Beers EJ; ACTIVATE Investigators. Mitapivat versus Placebo for Pyruvate Kinase Deficiency. N Engl J Med. 2022 Apr 14;386(15):1432-1442. doi: 10.1056/NEJMoa2116634. PMID: 35417638 Clinical Trial.
   https://pubmed.ncbi.nlm.nih.gov/35417638/
7. Ono K, Fujiwara T, Saito K, Nishizawa H, Takahashi N, Suzuki C, Ochi T, Kato H, Ishii Y, Onodera K, Ichikawa S, Fukuhara N, Onishi Y, Yokoyama H, Yamada R, Nakamura Y, Igarashi K, Harigae H. Congenital sideroblastic anemia model due to ALAS2 mutation is susceptible to ferroptosis. Sci Rep. 2022 May 30;12(1):9024. doi: 10.1038/s41598-022-12940-9.
   https://pubmed.ncbi.nlm.nih.gov/35637209/
8. Fukuhara N, Suehiro Y, Kato H, Kusumoto S, Coronado C, Rappold E, Zhao W, Li J, Gilmartin A, Izutsu　K. Parsaclisib in Japanese patients with relapsed or refractory B-cell lymphoma (CITADEL-111): A phase Ib study. Cancer Sci. 2022 May;113(5):1702-1711. doi: 10.1111/cas.15308. Epub 2022 Mar 15.
   https://pubmed.ncbi.nlm.nih.gov/35201656/
9. Perl AE, Hosono N, Montesinos P, Podoltsev N, Martinelli G, Panoskaltsis N, Recher C, Smith CC, Levis MJ, Strickland S, Röllig C, Groß-Langenhoff M, Chou WC, Lee JH, Yokoyama H, Hasabou N, Lu Q, Tiu RV, Altman JK. Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. Blood Cancer J. 2022 May 30;12(5):84. doi: 10.1038/s41408-022-00677-7. PMID: 35637252 Free PMC article.　
   https://pubmed.ncbi.nlm.nih.gov/35637252/
10. Murayama K, Kiguchi T, Izutsu K, Kameoka Y, Hidaka M, Kato H, Rai S, Kuroda J, Ishizawa K, Ichikawa S, Ando K, Ogura M, Fukushima K, Terui Y. Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma. Ann Hematol. 2022 May;101(5):979-989. doi: 10.1007/s00277-022-04801-2. Epub 2022 Mar 4.　PMID: 35244756 Free PMC article. Clinical Trial.
    https://pubmed.ncbi.nlm.nih.gov/35244756/
11. Handa H, Cheong JW, Onishi Y, Iida H, Kobayashi Y, Kim HJ, Chiou TJ, Izutsu K, Tsukurov O, Zhou X, Faessel H, Yuan Y, Sedarati F, Faller DV, Kimura A, Wu SJ. Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine. J Hematol Oncol. 2022 May 11;15(1):56. doi: 10.1186/s13045-022-01264-w. PMID: 35545778 Free PMC article. Clinical Trial.　
    https://pubmed.ncbi.nlm.nih.gov/35545778/
12. Onishi Y, Onodera K, Fukuhara N, Kato H, Ichikawa S, Fujiwara T, Yokoyama H, Fujiwara M, Harigae H. Unrelated cord blood transplantation for adult-onset EBV-associated T-cell and NK-cell lymphoproliferative disorders. Int J Hematol. 2022 Jun;115(6):873-881. doi: 10.1007/s12185-022-03313-z. Epub 2022 Mar 10.　
    https://pubmed.ncbi.nlm.nih.gov/35274195/
13. Sasaki K, Fujiwara T, Ochi T, Ono K, Kato H, Onodera K, Ichikawa S, Fukuhara N, Onishi Y, Yokoyama H, Miyata T, Harigae H. TM5614, an Inhibitor of Plasminogen Activator Inhibitor-1, Exerts an Antitumor Effect on Chronic Myeloid Leukemia. Tohoku J Exp Med. 2022 Jun 25;257(3):211-224. doi: 10.1620/tjem.2022.J036. Epub 2022 Apr 28.
    https://pubmed.ncbi.nlm.nih.gov/35491124/
14. Sekiguchi N, Rai S, Munakata W, Suzuki K, Handa H, Shibayama H, Endo T, Terui Y, Iwaki N, Fukuhara N, Tatetsu H, Iida S, Ishikawa T, Iguchi D, Izutsu K . Two-year outcomes of tirabrutinib monotherapy in Waldenström's macroglobulinemia. Cancer Sci. 2022 Jun;113(6):2085-2096. doi: 10.1111/cas.15344. Epub 2022 Apr 6.
    https://pubmed.ncbi.nlm.nih.gov/35332633/
15. Murakami S, Ri M, Ito M, Nakamura N, Kasahara S, Kitagawa J, Inagaki Y, Kuroda J, Yoshimitsu M, Okamoto A, Fukuhara N, Taji H, Iida H, Nagai H, Hanamura I, Tsujimura H, Okura M, Kurata M, Kuwatsuka Y, Atsuta Y, Iida S . Efficacy and safety of modified BLd therapy for Japanese patients with transplant-ineligible multiple myeloma. Int J Hematol. 2022 Oct;116(4):563-569. doi: 10.1007/s12185-022-03379-9. Epub 2022 Jun 14.　
    https://pubmed.ncbi.nlm.nih.gov/35699890/
16. Yamamoto M, Sato M, Onishi Y, Sasahara Y, Sano H, Masuko M, Nakamae H, Matsuoka KI, Ara T, Washio K, Onizuka M, Watanabe K, Takahashi Y, Hirakawa T, Nishio M, Sakashita C, Kobayashi T, Sawada A, Ichinohe T, Fukuda T, Hashii Y, Atsuta Y, Arai A. Registry data analysis of hematopoietic stem cell transplantation on systemic chronic active Epstein-Barr virus infection patients in Japan. Am J Hematol. 2022 Jun 1;97(6):780-790. doi: 10.1002/ajh.26544. Epub 2022 Mar 30. PMID: 35312194 Free article.　
    https://pubmed.ncbi.nlm.nih.gov/35312194/
17. Ichikawa S, Fukuhara N, Saito K, Onodera K, Onishi Y, Yokoyama H, Ichinohasama R, Harigae　H. Diffuse Large B-cell Lymphoma Presenting as Peritoneal Lymphomatosis: A Case Report and Literature Review. Intern Med. 2022 Jul 1;61(13):2057-2060. doi: 10.2169/internalmedicine.8793-21. Epub 2021 Dec 11.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC9334232/
18. Kanda J, Hirabayashi S, Yokoyama H, Kawase T, Tanaka H, Uchida N, Taniguchi S, Takahashi S, Onizuka M, Tanaka M, Sugio Y, Eto T, Kanda Y, Kimura T, Ichinohe T, Atsuta Y, Morishima S; Effect of Multiple HLA Locus Mismatches on Outcomes after Single Cord Blood Transplantation. Japanese Society for Transplantation and Cellular Therapy's HLA Working Group. Transplant Cell Ther. 2022 Jul;28(7):398.e1-398.e9. doi: 10.1016/j.jtct.2022.05.005. Epub 2022 May 13.　PMID: 35577322 Free article.　
    https://pubmed.ncbi.nlm.nih.gov/35577322/
19. Yokoyama H, Kanaya M, Iemura T, Hirayama M, Yamasaki S, Kondo T, Uchida N, Takahashi S, Tanaka M, Onizuka M, Ozawa Y, Kozai Y, Eto T, Sugio Y, Hamamura A, Kawakita T, Aotsuka N, Takada S, Wake A, Kimura T, Ichinohe T, Atsuta Y, Yanada M, Morishima S. Improved outcomes of single-unit cord blood transplantation for acute myeloid leukemia by killer immunoglobulin-like receptor 2DL1-ligand mismatch. Bone Marrow Transplant. 2022 Jul;57(7):1171-1179. doi: 10.1038/s41409-022-01700-y. Epub 2022 May 10.　
    https://pubmed.ncbi.nlm.nih.gov/35538140/
20. Ochi T, Fujiwara T, Ono　K, Suzuki C, Nikaido M, Inoue D, Kato H, Onodera K, Ichikawa S, Fukuhara N, Onishi Y, Yokoyama H, Nakamura　Y, Harigae H Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndrome. Sci Rep. 2022 Aug 26;12(1):14562. doi: 10.1038/s41598-022-18921-2. PMID: 36028755 Free PMC article.
    https://pubmed.ncbi.nlm.nih.gov/36028755/
21. Harigae H. The path from stem cells to red blood cells. Int J Hematol. 2022 Aug;116(2):160-162. doi: 10.1007/s12185-022-03413-w. Epub 2022 Jul 16.　PMID: 35841459 Review.
    https://pubmed.ncbi.nlm.nih.gov/35841459/
22. Nishimura JI, Usuki K, Ramos J, Ichikawa S, Buri M, Kiialainen A, Sostelly A, Peffault de Latour R, Paz-Priel I, Röth A. Crovalimab for treatment of patients with paroxysmal nocturnal haemoglobinuria and complement C5 polymorphism: Subanalysis of the phase 1/2 COMPOSER study. Br J Haematol. 2022 Aug;198(3):e46-e50. doi: 10.1111/bjh.18274. Epub 2022 May 24. PMID: 35608260 No abstract available.
    https://pubmed.ncbi.nlm.nih.gov/35608260/
23. Maruyama D, Iida S, Machida R, Kusumoto S, Fukuhara N, Yamauchi N, Miyazaki K, Yoshimitsu M, Kuroda J, Tsukamoto N, Tsujimura H, Usuki K, Yamauchi T, Utsumi T, Mizuno I, Takamatsu Y, Nagata Y, Ota S, Ohtsuka E, Hanamura I, Suzuki Y, Yoshida S, Yamasaki S, Suehiro Y, Kamiyama Y, Fukuhara S, Tsukasaki K, Nagai H. Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105). Cancer Sci. 2022 Sep;113(9):3267-3270. doi: 10.1111/cas.15484. Epub 2022 Jul 31. PMID: 35909244 Free PMC article. No abstract available.
    https://pubmed.ncbi.nlm.nih.gov/35909244/
24. Yokoyama H. Role of NK cells in cord blood transplantation and their enhancement by the missing ligand effect of the killer-immunoglobulin like receptor. Front Genet. 2022 Oct 18;13:1041468. doi: 10.3389/fgene.2022.1041468. eCollection 2022. PMID: 36330445 Free PMC article. Review　
    https://pubmed.ncbi.nlm.nih.gov/36330445/
25. Kanda Y, Doki N, Kojima M, Kako S, Inoue M, Uchida N, Onishi Y, Kamata R, Kotaki M, Kobayashi R, Tanaka J, Fukuda T, Fujii N, Miyamura K, Mori SI, Mori Y, Morishima Y, Yabe H, Atsuta Y, Kodera Y. Effect of Cryopreservation in Unrelated Bone Marrow and Peripheral Blood Stem Cell Transplantation in the Era of the COVID-19 Pandemic: An Update from the Japan Marrow Donor Program. Transplant Cell Ther. 2022 Oct;28(10):677.e1-677.e6. doi: 10.1016/j.jtct.2022.06.022. Epub 2022 Jul 6. PMID: 35803526 Free PMC article.
    https://pubmed.ncbi.nlm.nih.gov/35803526/
26. Suzuki C, Fujiwara T, Shima H, Ono K, Saito K, Kato H, Onodera K, Ichikawa S, Fukuhara N, Onishi Y, Yokoyama H, Nakamura Y, Igarashi K, Harigae H. Elucidation of the Role of FAM210B in Mitochondrial Metabolism and Erythropoiesis. Mol Cell Biol. 2022 Dec 15;42(12):e0014322. doi: 10.1128/mcb.00143-22. Epub 2022 Nov 14. PMID: 36374104 Free PMC article.
    https://pubmed.ncbi.nlm.nih.gov/36374104/

 

2021年

1. Maruyama D, Iida S, Ogawa G, Fukuhara N , Seo S, Miyazaki K, Yoshimitsu M, Kuroda J, Tsukamoto N, Tsujimura H, Hangaishi A, Yamauchi T, Utsumi T, Mizuno I, Takamatsu Y, Nagata Y, Minauchi K, Ohtsuka E , Hanamura I, Yoshida S, Yamasaki S, Suehiro Y, Kamiyama Y, Tsukasaki K, Naga H. Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105). Br J Haematol. 2021 Feb;192(3):531-541. doi: 10.1111/bjh.16878. Epub 2020 Jun 24.
   https://pubmed.ncbi.nlm.nih.gov/32583431/
2. Ohmachi K, Kinoshita T, Tobinai K, Ogawa G, Mizutani T , Yamauchi N, Fukuhara N, Uchida T , Yamamoto K , Miyazaki K, Tsukamoto N, Iida S , Utsumi T , Yoshida I, Imaizumi Y , Tokunaga T , Yoshida S , Masaki Y , Murayama T , Yakushijin Y, Suehiro Y , Nosaka K, Dobashi N , Kuroda J, Takamatsu Y, Maruyama D , Ando K, Ishizawa K , Ogura M , Yoshino T, Hotta T, Tsukasaki K, Nagai H, Japan Clinical Oncology Group A. randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial. Blood Adv. 2021 Feb 23;5(4):984-993. doi: 10.1182/bloodadvances.2020002567.
   https://pubmed.ncbi.nlm.nih.gov/33591324/
3. Taniguchi S, Yamauchi T , Choi I , Fukuhara N , Potluri J , Salem H.A. , Hong-W-H , Honda H, Nishimura Y , Okubo S, Usuki K. Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findings. Jpn J Clin Oncol. 2021 May 28;51(6):857-864. doi: 10.1093/jjco/hyab018.
   https://pubmed.ncbi.nlm.nih.gov/33712849/
4. Kawai H , Ando K , Maruyama F , Yamamoto K , Kiyohara E , Terui Y , Fukuhara N, Miyagaki T , Tokura Y , Yanagimoto-S -M , Igarashi T , Kuroda J , Fujita J , Uchida T , Ishikawa T, Yonekura K, Kato K , Nakanishi T , Nakai K , Matsunaga R, Tobinai K. Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma. Cancer Sci. 2021 Jun;112(6):2426-2435. doi: 10.1111/cas.14906. Epub 2021 May 3.
   https://pubmed.ncbi.nlm.nih.gov/33792128/
5. Terui Y, Rai S , Izutsu K, Yamaguchi M , Takizawa J, Kuroda J, Ishikawa T , Kato K , Suehiro Y, Fukuhara N, Ohmine K, Goto H, Yamamoto K, Kanemura N, Ueda Y, Ishizawa K, Kumagai K, Kawasaki A , Saito T , Hashizume M, Shibayama H. A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma. Cancer Sci. 2021 Jul;112(7):2845-2854. doi: 10.1111/cas.14937. Epub 2021 Jun 4.
   https://pubmed.ncbi.nlm.nih.gov/33942442/
6. Onodera K, Onishi Y, Inoue J, Tanaka Y, Yonha L, Ichikawa S, Fukuhara N, Yokoyama H, Murai K, Masamune A, Harigae H. Second direct-acting antiviral therapy for hepatitis C virus infection after umbilical cord blood transplantation: A case report. J Infect Chemother. 2021 Aug;27(8):1230-1233. doi: 10.1016/j.jiac.2021.02.002. Epub 2021 Feb 12.
   https://pubmed.ncbi.nlm.nih.gov/33589371/
7. Hirasawa T, Kikuchi M, Shigeta K, Takasaki S , Sato Y , Sato T, Ogura J, Onodera K, Fukuhara N, Onishi Y , Maekawa M, Mano N. High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma. Biomed Chromatogr. 2021 Aug;35(8):e5124. doi: 10.1002/bmc.5124. Epub 2021 Apr
   https://pubmed.ncbi.nlm.nih.gov/33772839/
8. Ichikawa S, Fujiwara T, Saito K, Sakurai K, Inokura K, Fukuhara N, Yokoyama H, Onodera K, Onishi Y, Kameoka J, Harigae H. Salvage Cord Blood Transplantation for Sustained Remission of Acute Megakaryoblastic Leukemia That Relapsed Early after Myeloablative Transplantation. Intern Med. 2021 Sep 15;60(18):3015-3019. doi: 10.2169/internalmedicine.6796-20. Epub 2021 Apr
   https://pubmed.ncbi.nlm.nih.gov/33814495/
9. Ichikawa S, Furukawa E, Saito K, Fukuhara N, Onodera K, Onishi Y, Yokoyama H, Ichinohasama R ,Harigae H. Sustained remission of giant pancreatic plasmacytoma with daratumumab. Ann Hematol. 2021 Oct;100(10):2633-2634. doi: 10.1007/s00277-020-04145-9. Epub 2020 Jun 18.
   https://pubmed.ncbi.nlm.nih.gov/32556544/
10. Ichikawa S, Fujiwara T, Saito K, Fukuhara N, Yokoyama H, Hatta S, Onodera K, Onishi Y, Fujishima F, Ichinohasama R, Harigae H. A novel case of γδ T cell leukemia with recurrent genetic abnormalities accompanied by agranulocytosis. Ann Hematol. 2021 Oct;100(10):2665-2668. doi: 10.1007/s00277-020-04241-w. Epub 2020 Aug 31.　
    https://pubmed.ncbi.nlm.nih.gov/32865606/
11. Fujishima F, Fukuhara N, Katsushima H, Nakamura Y, Harigae H, Sasano H, Ichinohasama R. Utility of a new notation to visualize flow cytometry analysis results: first preliminary comparison with immunohistochemistry to detect CD30 expression on T-cell lymphoma cells. BMC Cancer. 2021 Dec 20;21(1):1352. doi: 10.1186/s12885-021-09098-4.
    https://pubmed.ncbi.nlm.nih.gov/34930176/
12. Ichikawa S, Fukuhara N, Hashimoto K, Fujishima F, Ichinohasama R, Harigae H. Anaplastic multiple myeloma with MYC rearrangement. Leuk Res Rep. 2021 Dec 27;17:100288. doi: 10.1016/j.lrr.2021.100288. eCollection 2022.
    https://pubmed.ncbi.nlm.nih.gov/35024332/
13. Ri M, Iida S, Maruyama D, Sakabe A, Kamei R, Nakashima T, Tohkin M, Osaga S, Tobinai K , Fukuhara N, Miyazaki K, Tsukamoto N, Tsujimura H, Yoshimitsu M, Miyamoto K, Tsukasaki K, Nagai H. HLA genotyping in Japanese patients with multiple myeloma receiving bortezomib: An exploratory biomarker study of JCOG1105 (JCOG1105A1). Cancer Sci. 2021 Dec;112(12):5011-5019. doi: 10.1111/cas.15158. Epub 2021 Oct
    https://pubmed.ncbi.nlm.nih.gov/34626515/

 

2020年

1. Mutoh T, Shirai T, Ishii T, Shirota Y, Fujishima F, Takahashi F, Kakuta Y, Kanazawa Y, Masamune A, Saiki Y, Harigae H, Fujii H. Identification of two major autoantigens negatively regulating endothelial activation in Takayasu arteritis. Nat Commun. 2020 Mar 9;11(1):1253. doi: 10.1038/s41467-020-15088-0. PMID: 32152303; PMCID: PMC7062749.
2. Ichikawa S, Furukawa E, Saito K, Fukuhara N, Onodera K, Onishi Y, Yokoyama H, Ichinohasama R, Harigae H. Sustained remission of giant pancreatic plasmacytoma with daratumumab. Ann Hematol. 2020 Jun 18. doi: 10.1007/s00277-020-04145-9. Epub ahead of print. PMID: 32556544.
3. Ichikawa S, Fukuhara N, Shirai T, Ishii T, Ichinohasama R, Harigae H. Extranasal extranodal NK/T-cell lymphoma associated with systemic lupus erythematosus. Int J Hematol. 2020 Jun 8. doi: 10.1007/s12185-020-02914-w. Epub ahead of print. PMID: 32514927.
4. Ichikawa S, Saito K, Fukuhara N, Tanaka Y, Lee Y, Onodera K, Onishi Y, Yokoyama H, Fujiwara M, Harigae H. Successful Treatment of Life-threatening Bleeding Caused by Acquired Factor X Deficiency Associated with Respiratory Infection. Intern Med. 2020 May 15;59(10):1303-1308. doi: 10.2169/internalmedicine.4142-19. Epub 2020 Feb 5. PMID: 32023586; PMCID: PMC7303456.
5. Ichikawa S, Fukuhara N, Saito K, Yokoyama H, Onodera K, Onishi Y, Ichinohasama R, Harigae H. Epstein-Barr virus-positive diffuse large B-cell lymphoma after sustained remission of T-cell prolymphocytic leukemia with alemtuzumab. Leuk Lymphoma. 2020 Jun;61(6):1504-1507. doi: 10.1080/10428194.2020.1713322. Epub 2020 Jan 21. PMID: 31960738.
6. Ichikawa S, Fukuhara N, Saito K, Onodera K, Shirai T, Onishi Y, Yokoyama H, Fujii H, Ichinohasama R, Harigae H. Successful treatment of methotrexate-associated classical Hodgkin lymphoma with brentuximab vedotin-combined chemotherapy: a case series. Int J Hematol. 2020 May;111(5):667-672. doi: 10.1007/s12185-020-02822-z. Epub 2020 Jan 18. PMID: 31955346.
7. Ichikawa S, Fukuhara N, Watanabe S, Okitsu Y, Onodera K, Onishi Y, Harigae H. Long-term survival after cord blood transplantation for acute myeloid leukemia complicated with disseminated fusariosis. J Infect Chemother. 2020 Feb;26(2):292-295. doi: 10.1016/j.jiac.2019.08.022. Epub 2019 Sep 28. PMID: 31570321.
8. Ichikawa S, Sasaoka A, Fukuhara N, Okitsu Y, Onishi Y, Ichihohasama R, Harigae H. Primary ovarian diffuse large B-cell lymphoma preceded by autoimmune hemolytic anemia. J Hematopathol. 2020;13(1):63-67. doi: 10.1007/s12308-019-00377-5.
9. Shirai T, Mori Y, Izumiyama T, Fujii H, Ishii T, Harigae H. Rheumatoid Arthritis After Cord Blood Cell Transplantation. J Clin Rheumatol. 2020 Jun 12. doi: 10.1097/RHU.0000000000001430. Epub ahead of print. PMID: 32541615.
10. Shirai T, Komatsu H, Sato H, Fujii H, Ishii T, Harigae H. Migratory Aortitis Associated with Granulocyte-colony-stimulating Factor. Intern Med. 2020 Jun 15;59(12):1559-1563. doi: 10.2169/internalmedicine.4331-19. Epub 2020 Mar 19. PMID: 32188815.
11. Shirai T, Murakami K, Fujii H, Ishii T, Harigae H. Comment on: Aortarctia: a rare manifestation of relapsing polychondrits. Rheumatology (Oxford). 2020 Jul 1;59(7):1784-1785. doi: 10.1093/rheumatology/keaa019. PMID: 32025723.
12. Yokoyama H, Takenaka K, Nishida T, Seo S, Shinohara A, Uchida N, Tanaka M, Takahashi S, Onizuka M, Kozai Y, Yasuhiro S, Ozawa Y, Katsuoka Y, Doki N, Sawa M, Kimura T, Kanda J, Fukuda T, Atsuta Y, Nakasone H; Japan Society for Hematopoietic Cell Transplantation Transplantation-Related Complication Working Group. Favorable Effect of Cytomegalovirus Reactivation on Outcomes in Cord Blood Transplant and Its Differences Among Disease Risk or Type. Biol Blood Marrow Transplant. 2020 Jul;26(7):1363-1370. doi: 10.1016/j.bbmt.2020.04.002. Epub 2020 Apr 18. PMID: 32311477.
13. Yokoyama H, Morishima Y, Fuji S, Uchida N, Takahashi S, Onizuka M, Tanaka M, Yuju O, Eto T, Ozawa Y, Takada S, Takanashi M, Kato K, Kanda Y, Ichinohe T, Atsuta Y, Kanda J; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation. Impact of HLA Allele Mismatch at HLA-A, -B, -C, and -DRB1 in Single Cord Blood Transplantation. Biol Blood Marrow Transplant. 2020 Mar;26(3):519-528. doi: 10.1016/j.bbmt.2019.11.001. Epub 2019 Nov 9. PMID:31715305.
14. Ishii Y, Fujii H, Sugimura K, Shirai T, Hoshi Y, Fujita Y, Shirota Y, Ishii T, Shimokawa H, Harigae H. Successful Treatment of Pulmonary Arterial Hypertension in Systemic Sclerosis with Anticentriole Antibody. Case Rep Rheumatol. 2020 Feb 25;2020:1926908. doi: 10.1155/2020/1926908. PMID: 32158583; PMCID: PMC7061130.
15. Okazaki S, Watanabe R, Kondo H, Kudo M, Harigae H, Fujii H. High Relapse Rate in Patients with Polymyalgia Rheumatica despite the Combination of Immunosuppressants and Prednisolone: A Single Center Experience of 89 patients. Tohoku J Exp Med. 2020 Jun;251(2):125-133. doi: 10.1620/tjem.251.125. PMID: 32581186.
16. Okazaki S, Watanabe R, Harigae H, Fujii H. Better Retention of Abatacept Is Associated with High Rheumatoid Factor: A Five-Year Follow-Up Study of Patients with Rheumatoid Arthritis. Tohoku J Exp Med. 2020 Mar;250(3):153-159. doi: 10.1620/tjem.250.153. PMID: 32132324.
17. Takahashi T, Ichikawa S, Ichinohasama R, Harigae H. BCR-ABL1 positive lymphoblastic lymphoma - should it be treated like a B-lymphoblastic leukemia with t(9;22);BCR-ABL1? Leuk Lymphoma. 2020 May;61(5):1265-1267. doi: 10.1080/10428194.2019.1706736. Epub 2019 Dec 26. PMID: 31876209.
18. Sekiguchi N, Rai S, Munakata W, Suzuki K, Handa H, Shibayama H, Endo T, Terui Y, Iwaki N, Fukuhara N, Tatetsu H, Iida S, Ishikawa T, Shiibashi R, Izutsu K. A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia. Cancer Sci. 2020 Jul 8. doi: 10.1111/cas.14561. Epub ahead of print. PMID: 32639651.
19. Yonese I, Sakashita C, Imadome KI, Kobayashi T, Yamamoto M, Sawada A, Ito Y, Fukuhara N, Hirose A, Takeda Y, Makita M, Endo T, Kimura SI, Ishimura M, Miura O, Ohga S, Kimura H, Fujiwara S, Arai A. Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification. Blood Adv. 2020 Jul 14;4(13):2918-2926. doi: 10.1182/bloodadvances.2020001451. PMID: 32598475; PMCID: PMC7362364.
20. Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N, Kitagawa J, Aoi A, Nishikawa R. Phase 1/2 Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Relapsed/Refractory Primary Central Nervous System Lymphoma. Neuro Oncol. 2020 Jun 25:noaa145. doi: 10.1093/neuonc/noaa145. Epub ahead of print. PMID: 32583848.
21. Maruyama D, Iida S, Ogawa G, Fukuhara N, Seo S, Miyazaki K, Yoshimitsu M, Kuroda J, Tsukamoto N, Tsujimura H, Hangaishi A, Yamauchi T, Utsumi T, Mizuno I, Takamatsu Y, Nagata Y, Minauchi K, Ohtsuka E, Hanamura I, Yoshida S, Yamasaki S, Suehiro Y, Kamiyama Y, Tsukasaki K, Nagai H. Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105). Br J Haematol. 2020 Jun 24. doi: 10.1111/bjh.16878. Epub ahead of print. PMID: 32583431.
22. Terakura S, Nishida T, Sawa M, Kato T, Miyao K, Ozawa Y, Goto T, Kohno A, Ozeki K, Onishi Y, Fukuhara N, Fujii N, Yokoyama H, Kasai M, Iida H, Kanemura N, Endo T, Ago H, Onizuka M, Iyama S, Nawa Y, Nakamae M, Nagata Y, Kurahashi S, Tomiya Y, Yanagisawa A, Suzuki R, Kuwatsuka Y, Atsuta Y, Miyamura K, Murata M; Nagoya Blood and Marrow Transplantation Group. Prospective evaluation of alternative donor from unrelated donor and cord blood in adult acute leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2020 Jul;55(7):1399-1409. doi: 10.1038/s41409-020-0859-8. Epub 2020 Mar 16. PMID: 32203259.
23. Shimada K, Yamaguchi M, Atsuta Y, Matsue K, Sato K, Kusumoto S, Nagai H, Takizawa J, Fukuhara N, Nagafuji K, Miyazaki K, Ohtsuka E, Okamoto M, Sugita Y, Uchida T, Kayukawa S, Wake A, Ennishi D, Kondo Y, Izumi T, Kin Y, Tsukasaki K, Hashimoto D, Yuge M, Yanagisawa A, Kuwatsuka Y, Shimada S, Masaki Y, Niitsu N, Kiyoi H, Suzuki R, Tokunaga T, Nakamura S, Kinoshita T. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020 Apr;21(4):593-602. doi: 10.1016/S1470-2045(20)30059-0. Epub 2020 Mar 11. PMID: 32171071.
24. Kusumoto S, Tanaka Y, Suzuki R, Watanabe T, Nakata M, Sakai R, Fukushima N, Fukushima T, Moriuchi Y, Itoh K, Nosaka K, Choi I, Sawa M, Okamoto R, Tsujimura H, Uchida T, Suzuki S, Okamoto M, Takahashi T, Sugiura I, Onishi Y, Kohri M, Yoshida S, Kojima M, Takahashi H, Tomita A, Atsuta Y, Maruyama D, Tanaka E, Suzuki T, Kinoshita T, Ogura M, Ueda R, Mizokami M. Ultra-high sensitivity HBsAg assay can diagnose HBV reactivation following rituximab-based therapy in patients with lymphoma. J Hepatol. 2020 Mar 17:S0168-8278(20)30167-7. doi: 10.1016/j.jhep.2020.03.009. Epub ahead of print. PMID: 32194183.
25. Yabe H, Tabuchi K, Uchida N, Takahashi S, Onishi Y, Aotsuka N, Sugio Y, Ikegame K, Ichinohe T, Takahashi M, Kato K, Atsuta Y, Kanda Y. Could the minimum number of haematopoietic stem cells to obtain engraftment exist in unrelated, single cord blood transplantation? Br J Haematol. 2020 Apr;189(2):e56-e60. doi: 10.1111/bjh.16465. Epub 2020 Feb 28. PMID: 32108331.
26. Nishikawa K, Kimura K, Kanda Y, Sugiyama M, Kakihana K, Doki N, Ohashi K, Bae SK, Takahashi K, Ishihara Y, Mizuno I, Onishi Y, Onozawa M, Onizuka M, Yamamoto M, Ishikawa T, Inoue K, Kusumoto S, Hashino S, Saito H, Kanto T, Sakamaki H, Mizokami M. A prospective trial of vaccine to prevent hepatitis B virus reactivation after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2020 Jul;55(7):1388-1398. doi: 10.1038/s41409-020-0833-5. Epub 2020Feb 18. PMID: 32071416; PMCID: PMC7329632.
27. Harada K, Fuji S, Seo S, Kanda J, Ueki T, Kimura F, Kato K, Uchida N, Ikegame K, Onizuka M, Matsuoka KI, Doki N, Kawakita T, Onishi Y, Yano S, Fukuda T, Takanashi M, Kanda Y, Atsuta Y, Ogata M; transplant complications working group of the Japan Society for Hematopoietic Cell Transplantation. Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2020 Feb 12. doi: 10.1038/s41409-020-0821-9. Epub ahead of print. PMID: 32051535.
28. Ichikawa S, Saito K, Fukuhara N, Yokoyama H, Onodera K,Onishi Y, Ichinohasama R, Harigae H. Primary adrenal extranodal NK/T-cell lymphoma: A case report and literature review. Leuk Res Rep. 2020 Sep 28;14:100223. doi: 10.1016/j.lrr.2020.100223. eCollection 2020.
    https://pubmed.ncbi.nlm.nih.gov/33024692/
29. Ichikawa S, Fukuhara N, Shirai T, Ishii T, Ichinohasama R , Harigae H. Extranasal extranodal NK/T-cell lymphoma associated with systemic lupus erythematosus. Case Reports Int J Hematol. 2020 Oct;112(4):592-596. doi: 10.1007/s12185-020-02914-w. Epub 2020 Jun 8.
    https://pubmed.ncbi.nlm.nih.gov/32514927/
30. Yasushi Onishi , Hisayuki Yokoyama , Yuna Katsuoka , Toshihiro Ito , Tomohumi Kimura , Joji Yamamoto , Shinji Nakajima , Osamu Sasaki , Takahide Ara , Koichiro Minauchi , Osamu Fukuhara , Naoki Kobayashi , Hideyoshi Noji , Shuichi Ota , Hideo Harigae. Low-dose lenalidomide and dexamethasone therapy after melphalan-prednisolone induction in elderly patients with newly diagnosed multiple myeloma. Ann Hematol. 2020 Oct;99(10):2351-2356. doi: 10.1007/s00277-020-04240-x. Epub 2020 Aug 31.
    https://pubmed.ncbi.nlm.nih.gov/32865607/
31. Ichikawa S , Fukuhara N, Saito K , Furukawa E, Onodera K , Onishi Y, Yokoyama H, Ichinohasama R, Harigae H. Successful Treatment of Primary Refractory Angioimmunoblastic T-cell Lymphoma With Cord Blood Transplantation. Clin Lymphoma Myeloma Leuk. 2020 Nov;20(11):e926-e929. doi: 10.1016/j.clml.2020.07.009. Epub 2020 Jul 22.
    https://pubmed.ncbi.nlm.nih.gov/32792303/
32. Fukuhara N, Kinoshita T, Yamamoto K, Nagai H , Izutsu K, Yamamoto G, Bhargava P, Rajakumaraswamy N, Humeniuk R, Mathias A, Xing G, Fukui M, Tobinai K. Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia. Jpn J Clin Oncol. 2020 Dec 16;50(12):1395-1402. doi: 10.1093/jjco/hyaa153.
    https://pubmed.ncbi.nlm.nih.gov/32856068/

 

 

2019年

1. Nakagawa R, Onishi Y, Kawajiri A, Onodera K, Furukawa E, Sano S, Saito K, Ichikawa S, Fujiwara T, Fukuhara N, Harigae H. Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma. Ann Hematol. 2019 Aug;98(8):1999-2001. doi: 10.1007/s00277-019-03645-7.
2. Mutoh T, Ishii T, Shirai T, Akita K, Kamogawa Y, Fujita Y, Sato H, Shirota Y, Fujii H, Harigae H. Refractory Takayasu arteritis successfully treated withrituximab: case-based review. Rheumatol Int. 2019 Aug 6. doi:10.1007/s00296-019-04390-w. 4: Mutoh T, Shirai T, Fujii H, Ishii T, Harigae H. Insufficient use of corticosteroids without immunosuppressants results in higher relapse in Takayasu arteritis. J Rheumatol. 2019 May 15. pii: jrheum.181219. doi:10.3899/jrheum.181219.
3. Shirai T, Shirota Y, Fujii H, Ishii T, Harigae H. Four distinct clinical phenotypes of vasculitis affecting medium-sized arteries. Scand J Rheumatol. 2019 Jul;48(4):308-314. doi: 10.1080/03009742.2018.1551965.
4. Saito K, Fujiwara T, Hatta S, Morita M, Ono K, Suzuki C, Fukuhara N, Onishi Y, Nakamura Y, Kawamata S, Shimizu R, Yamamoto M, Harigae H. Generation and Molecular Characterization of Human Ring Sideroblasts: a Key Role of Ferrous Iron in Terminal Erythroid Differentiation and Ring Sideroblast Formation. Mol Cell Biol. 2019 Mar 19;39(7). pii: e00387-18. doi: 10.1128/MCB.00387-18.
5. Ochi T, Onishi Y, Nasu K, Onodera K, Kobayashi M, Ichikawa S, Fujiwara T, Fukuhara N, Yamada-Fujiwara M, Harigae H. Umbilical Cord Blood Transplantation Using Reduced-Intensity Conditioning without Antithymocyte Globulin in Adult Patients with Severe Aplastic Anemia. Biol Blood Marrow Transplant. 2019 Feb;25(2):e55-e59. doi: 10.1016/j.bbmt.2018.09.039.
6. Fujiwara T, Harigae H. Molecular pathophysiology and genetic mutations in congenital sideroblastic anemia. Free Radic Biol Med. 2019 Mar;133:179-185. doi:10.1016/j.freeradbiomed.2018.08.008.
7. Harigae H, Hino K, Toyokuni S. Iron as Soul of Life on Earth Revisited: From Chemical Reaction, Ferroptosis to Therapeutics. Free Radic Biol Med. 2019 Mar;133:1-2. doi: 10.1016/j.freeradbiomed.2019.01.042.
8. Yokoyama H, Kanda J, Kato S, Kondo E, Maeda Y, Saji H, Takahashi S, Onizuka M, Onishi Y, Ozawa Y, Kanamori H, Ishikawa J, Ohno Y, Ichinohe T, Takanashi M, Kato K, Atsuta Y, Kanda Y; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation. Effects of HLA mismatch on cytomegalovirus reactivation in cord blood transplantation. Bone Marrow Transplant. 2019 Jul;54(7):1004-1012. doi: 10.1038/s41409-018-0369-0. PMID: 30401965
9. Fukuhara N, Ishizawa K. Current approaches and future perspectives for advanced-stage follicular lymphoma with a low tumor burden. Jpn J Clin Oncol. 2019 Apr 1;49(4):306-310. doi: 10.1093/jjco/hyz008. PMID: 30715424.
10. Takahashi T, Ichikawa S, Harigae H. Successful cord blood transplantation for a paroxysmal nocturnal hemoglobinuria complicated with Budd-Chiari syndrome and myelodysplastic syndrome. Ann Hematol. 2019 Aug 9. doi:10.1007/s00277-019-03781-0.
11. Fujishima F, Katsushima H, Fukuhara N, Konosu-Fukaya S, Nakamura Y, Usubuchi H, Sato S, Ota Y, Yashima-Abo A, Nakamura T, Nakaya N, Harigae H, Sasano H, Ichinohasama R. Immunohistochemical pattern of c-MYC protein judged as "+/(weak)+/-" by a new notation correlates with MYC gene nontranslocation in large B-cell lymphoma. Hum Pathol. 2019 Mar;85:112-118. doi:10.1016/j.humpath.2018.10.025.
12. Iwaki K, Fujiwara T, Ito T, Suzuki C, Sasaki K, Ono K, Saito K, Fukuhara N, Onishi Y, Yokoyama H, Fujimaki S, Tanaka T, Tamura H, Fujiwara M, Harigae H. Flow Cytometry-Based Photodynamic Diagnosis with 5-Aminolevulinic Acid for the Detection of Minimal Residual Disease in Multiple Myeloma. Tohoku J Exp Med. 2019 Sep;249(1):19-28. doi: 10.1620/tjem.249.19. PMID: 31511451.
13. Röth A, Nishimura JI, Nagy Z, Gaàl-Weisinger J, Panse J, Yoon SS, Egyed M, Ichikawa S, Ito Y, Kim JS, Ninomiya H, Schrezenmeier H, Sica S, Usuki K, Sicre de Fontbrune F, Soret J, Sostelly A, Higginson J, Dieckmann A, Gentile B, Anzures-Cabrera J, Shinomiya K, Jordan G, Biedzka-Sarek M, Klughammer B, Jahreis A, Bucher C, Peffault de Latour R. The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood. 2020 Mar 19;135(12):912-920. doi: 10.1182/blood.2019003399. PMID: 31978221; PMCID: PMC7082616.
14. Kondo H, Watanabe R, Okazaki S, Kuriyama K, Harigae H, Fujii H. Coexistence of rheumatoid arthritis and systemic lupus erythematosus is still rare in the biologic era: Report of seven cases and literature review. Mod Rheumatol. 2019 Oct 30:1-2. doi: 10.1080/14397595.2019.1682795. Epub ahead of print. PMID: 31625433.
15. Akaishi T, Yasaka K, Abe M, Fujii H, Watanabe M, Shirai T, Ishizawa K, Takayama S, Kagaya Y, Harigae H, Ishii T. Protein-losing gastroenteropathy with severe hypoalbuminemia associated with Sjögren's syndrome: A case report and review of the literature. J Gen Fam Med. 2019 Oct 16;21(1):24-28. doi: 10.1002/jgf2.281. PMID: 31911886; PMCID: PMC6942935.
16. Kedar PS, Harigae H, Ito E, Muramatsu H, Kojima S, Okuno Y, Fujiwara T, Dongerdiye R, Warang PP, Madkaikar MR. Study of pathophysiology and molecular characterization of congenital anemia in India using targeted next-generation sequencing approach. Int J Hematol. 2019 Aug 10. doi: 10.1007/s12185-019-02716-9.
17. Kizaki M, Takahashi N, Iriyama N, Okamoto S, Ono T, Usui N, Inokuchi K, Nakaseko C, Kurokawa M, Sumi M, Nakamura F, Kawaguchi T, Suzuki R, Yamamoto K, Ohnishi K, Matsumura I, Naoe T; New TARGET investigators. Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system. Int J Hematol. 2019 Apr;109(4):426-439. doi:10.1007/s12185-019-02613-1.
18. Nakamura N, Izumi R, Hoshi Y, Takai Y, Ono R, Suzuki N, Nagai T, Ishii Y, Ishii T, Harigae H, Okada S, Aiba S, Okiyama N, Fujimoto M, Kuroda H, Tateyama M, Aoki M. FDG-PET detects extensive calcinosis cutis in anti-NXP2 antibody-positive dermatomyositis. Rheumatology (Oxford). 2019 Mar 16. pii: kez083. doi:10.1093/rheumatology/kez083.
19. Fukuhara N, Yamamoto G, Tsujimura H, Chou T, Shibayama H, Yanai T, Shibuya K, Izutsu K. Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study. Leuk Lymphoma. 2020 Jan;61(1):176-180. doi: 10.1080/10428194.2019.1654100. Epub 2019 Aug 22. PMID: 31437057.
20. Maruyama D, Nagai H, Fukuhara N, Kitano T, Ishikawa T, Nishikawa T. Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma. J Clin Exp Hematop. 2019;59(2):98-100. doi: 10.3960/jslrt.19006. PMID: 31257351; PMCID: PMC6661957.
21. Munakata W, Ando K, Hatake K, Fukuhara N, Kinoshita T, Fukuhara S, Shirasugi Y, Yokoyama M, Ichikawa S, Ohmachi K, Gion N, Aoi A, Tobinai K. Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan. Cancer Sci. 2019 May;110(5):1686-1694. doi: 10.1111/cas.13983. Epub 2019 Mar 28. PMID: 30815927; PMCID: PMC6500982.
22. Tobinai K, Uchida T, Fukuhara N, Nishikawa T. Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study. Int J Hematol. 2019 Mar;109(3):366-368. doi: 10.1007/s12185-018-02577-8. Epub 2019 Jan 8. PMID: 30623356.
23. Konuma T, Shimomura Y, Ozawa Y, Ueda Y, Uchida N, Onizuka M, Akiyama M, Mori T, Nakamae H, Ohno Y, Shiratori S, Onishi Y, Kanda Y, Fukuda T, Atsuta Y, Ishiyama K; Adult Myelodysplastic Syndrome Working Group of the Japan Society for Hematopoietic Cell Transplantation. Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: A propensity score matched analysis. Hematol Oncol. 2019 Feb;37(1):85-95. doi: 10.1002/hon.2566. Epub 2018 Nov 19. PMID: 30370627.
24. Kurosawa S, Yamaguchi T, Oshima K, Yanagisawa A, Fukuda T, Kanamori H, Mori T, Takahashi S, Kondo T, Fujisawa S, Onishi Y, Yano S, Onizuka M, Kanda Y, Mizuno I, Taniguchi S, Yamashita T, Inamoto Y, Okamoto S, Atsuta Y. Employment status was highly associated with quality of life after allogeneic hematopoietic cell transplantation, and the association may differ according to patient age and graft-versus-host disease status: analysis of a nationwide QOL survey. Bone Marrow Transplant. 2019 Apr;54(4):611-615. doi: 10.1038/s41409-018-0343-x. Epub 2018 Oct 4. PMID: 30287939.
25. Yakushijin K, Ikezoe T, Ohwada C, Kudo K, Okamura H, Goto H, Yabe H, Yasumoto A, Kuwabara H, Fujii S, Kagawa K, Ogata M, Onishi Y, Kohno A, Watamoto K, Uoshima N, Nakamura D, Ota S, Ueda Y, Oyake T, Koike K, Mizuno I, Iida H, Katayama Y, Ago H, Kato K, Okamura A, Kikuta A, Fukuda T. Clinical effects of recombinant thrombomodulin and defibrotide on sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2019 May;54(5):674-680. doi: 10.1038/s41409-018-0304-4. Epub 2018 Aug 20. PMID: 30127466.

 

 

2018年

1. Kato H, Itoh-Nakadai A, Matsumoto M, Ishii Y, Watanabe-Matsui M, Ikeda M, Ebina-Shibuya R, Sato Y, Kobayashi M, Nishizawa H, Suzuki K, Muto A, Fujiwara T, Nannya Y, Malcovati L, Cazzola M, Ogawa S, Harigae H, Igarashi K. Infection perturbs Bach2- and Bach1-dependent erythroid lineage 'choice' to cause anemia. Nat Immunol. 2018 Oct;19(10):1059-1070. doi: 10.1038/s41590-018-0202-3.
2. Hatta S, Fujiwara T, Yamamoto T, Saito K, Kamata M, Tamai Y, Kawamata S, Harigae H. A defined culture method enabling the establishment of ring sideroblasts from induced pluripotent cells of X-linked sideroblastic anemia. Haematologica. 2018 May;103(5):e188-e191. doi: 10.3324/haematol.2017.179770.
3. Ichikawa S, Fukuhara N, Onishi Y, Ichinohasama R, Harigae H. Sustained Remission of γδ T-Cell Lymphoma by Graft-Versus-Lymphoma Effect That Relapsed Early After Cord Blood Transplantation. Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):e369-e372. doi: 10.1016/j.clml.2018.06.019.
4. Ichikawa S, Fukuhara N, Hatta S, Himuro M, Katsushima H, Nasu K, Ono K, Inokura K, Kobayashi M, Onishi Y, Fujii H, Ishizawa K, Ichinohasama R, Harigae H. Successful Cord Blood Stem Cell Transplantation for Primary Cutaneous CD8-positive Aggressive Epidermotropic Cytotoxic T-cell Lymphoma Complicated with Cerebral Infiltration. Intern Med. 2018 Jul 15;57(14):2051-2055. doi:10.2169/internalmedicine.0568-17.
5. Ichikawa S, Fukuhara N, Hatta S, Himuro M, Nasu K, Ono K, Okitsu Y, Kobayashi M, Onishi Y, Ri M, Ichinohasama R, Harigae H. Anaplastic multiple myeloma: possible limitations of conventional chemotherapy for long-term remission. J Clin Exp Hematop. 2018;58(1):39-42. doi: 10.3960/jslrt.17035.
6. Ono K, Onishi Y, Kobayashi M, Hatta S, Nasu K, Watanabe S, Ichikawa S, Okitsu Y, Fukuhara N, Harigae H. γδ T cell clonal proliferation early after PD-1 blockade. Ann Hematol. 2019 Jan;98(1):219-220. doi: 10.1007/s00277-018-3406-6.
7. Ono K, Onishi Y, Kobayashi M, Ichikawa S, Hatta S, Watanabe S, Okitsu Y, Fukuhara N, Ichinohasama R, Harigae H. Successful Treatment of Aggressive Mature B-cell Lymphoma Mimicking Immune Thrombocytopenic Purpura. Intern Med. 2018 Sep1;57(17):2573-2579. doi: 10.2169/internalmedicine.0560-17.
8. Ishii Y, Shirai T, Hoshi Y, Fujita Y, Shirota Y, Fujii H, Ishii T, Harigae H. Nasal Septal Perforation in Propylthiouracil-Induced Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Case Rep Rheumatol. 2018 Mar 22;2018:8192021. doi: 10.1155/2018/8192021.
9. Machiyama T, So T, Okuyama Y, Kobayashi S, Phung HT, Asao A, Harigae H, Ishii N. TNF receptor associated factor 5 controls oncostatin M-mediated lung inflammation. Biochem Biophys Res Commun. 2018 May 15;499(3):544-550. doi:10.1016/j.bbrc.2018.03.186.
10. Shirai T, Hanaoka R, Goto Y, Kojima I, Ishii Y, Hoshi Y, Fujita Y, Shirota Y, Fujii H, Ishii T, Harigae H. Takayasu Arteritis Coexisting with Sclerosing Osteomyelitis. Intern Med. 2018 Jul 1;57(13):1929-1934. doi:10.2169/internalmedicine.0329-17.
11. Ishii T, Tanaka Y, Kawakami A, Saito K, Ichinose K, Fujii H, Shirota Y, Shirai T, Fujita Y, Watanabe R, Chiu SW, Yamaguchi T, Harigae H. Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus. Mod Rheumatol. 2018 Nov;28(6):986-992. doi: 10.1080/14397595.2018.1432331.
12. Ohashi K, Fujiwara T, Onodera K, Saito Y, Ichikawa S, Kobayashi M, Okitsu Y, Fukuhara N, Onishi Y, Harigae H. Establishment of a Screening System to Identify Novel GATA-2 Transcriptional Regulators. Tohoku J Exp Med. 2018 Jan;244(1):41-52. doi: 10.1620/tjem.244.41.
13. Harigae H. Iron metabolism and related diseases: an overview. Int J Hematol. 2018 Jan;107(1):5-6. doi: 10.1007/s12185-017-2384-0.
14. Shimada S, Nakamichi T, Yamada G, Narumi K, Usubuchi H, Yamamoto T, Ichikawa S, Fukuhara N, Miyazaki M, Harigae H, Sato H, Ito S. Concurrent isolated IgG2-positive membranous nephropathy and malignant B-cell lymphoma. CEN Case Rep. 2018 Nov;7(2):248-252. doi: 10.1007/s13730-018-0336-z.
15. Ishida H, Imamura T, Morimoto A, Fujiwara T, Harigae H. Five-aminolevulinic acid: New approach for congenital sideroblastic anemia. Pediatr Int. 2018 May;60(5):496-497. doi: 10.1111/ped.13558.
16. Mishima E, Suzuki T, Takeuchi Y, Seiji K, Fukuhara N, Takase K, Harigae H, Abe T, Ito S. Renovascular hypertension associated with JAK2 V617F positive myeloproliferative neoplasms treated with angioplasty: 2 cases and literature review. J Clin Hypertens (Greenwich). 2018 Apr;20(4):798-804. doi:10.1111/jch.13257.
17. Watanabe T, Tobinai K, Wakabayashi M, Morishima Y, Kobayashi H, Kinoshita T, Suzuki T, Yamaguchi M, Ando K, Ogura M, Taniwaki M, Uike N, Yoshino T, Nawano S, Terauchi T, Hotta T, Nagai H, Tsukasaki K; JCOG0203 Collaborators. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial. Lancet Haematol. 2018 Nov;5(11):e520-e531. doi: 10.1016/S2352-3026(18)30155-8.
18. Kawakami T, Nakazawa H, Kawakami F, Matsuzawa S, Sudo Y, Sakai H, Nishina S, Senoo N, Senoo Y, Komatsu M, Umemura T, Yamaguchi T, Kosho T, Fujiwara T, Harigae H, Ishida F. [Successful treatment of X-linked sideroblastic anemia with ALAS2 R452H mutation using vitamin B(6)]. Rinsho Ketsueki. 2018;59(4):401-406. doi:10.11406/rinketsu.59.401.
19. Kameoka Y, Akagi T, Murai K, Noji H, Kato Y, Sasaki O, Ito S, Ishizawa K, Ishida Y, Ichinohasama R, Harigae H, Takahashi N. Safety and efficacy of high-dose ranimustine (MCNU) containing regimen followed by autologous stem cell transplantation for diffuse large B-cell lymphoma. Int J Hematol. 2018 Nov;108(5):510-515. doi: 10.1007/s12185-018-2508-1.
20. Noguchi S, Nakaseko C, Nishiwaki K, Ogasawara H, Ohishi K, Tokuhira M, Noguchi M, Kimura H, Handa H, Mitani K, Miura M, Wakita H, Takahashi N; STAT study group. Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan. Int J Hematol. 2018 Aug;108(2):176-183. doi:10.1007/s12185-018-2459-6.
21. Murakami S, Suzuki T, Yokoyama W, Yagi S, Matsumura K, Nakajima Y, Harigae H, Fukamizu A, Motohashi H. Nucleomethylin deficiency impairs embryonic erythropoiesis. J Biochem. 2018 May 1;163(5):413-423. doi: 10.1093/jb/mvx086.PubMed PMID: 29244083.

 

 

2017年

1. Kobayashi M, Kato H, Hada H, Itoh-Nakadai A, Fujiwara T, Muto A, Inoguchi Y, Ichiyanagi K, Hojo W, Tomosugi N, Sasaki H, Harigae H, Igarashi K. Iron-heme-Bach1 axis is involved in erythroblast adaptation to iron deficiency. Haematologica. 2017 Mar;102(3):454-465. doi: 10.3324/haematol.2016.151043.
2. Saito K, Fujiwara T, Ota U, Hatta S, Ichikawa S, Kobayashi M, Okitsu Y, Fukuhara N, Onishi Y, Ishizuka M, Tanaka T, Harigae H. Dynamics of absorption, metabolism, and excretion of 5-aminolevulinic acid in human intestinal Caco-2 cells. Biochem Biophys Rep. 2017 Jul 13;11:105-111. doi:10.1016/j.bbrep.2017.07.006.
3. Hasegawa S, Fujiwara T, Okitsu Y, Kato H, Sato Y, Fukuhara N, Onishi Y, Shimizu R, Yamamoto M, Harigae H. Effects of in vivo deletion of GATA2 in bone marrow stromal cells. Exp Hematol. 2017 Dec;56:31-45.e2. doi:10.1016/j.exphem.2017.08.004.
4. Fujiwara T, Fukuhara N, Ichikawa S, Kobayashi M, Okitsu Y, Onishi Y, Furuyama K, Harigae H. A novel heterozygous ALAS2 mutation in a female with macrocytic sideroblastic anemia resembling myelodysplastic syndrome with ring sideroblasts: a case report and literature review. Ann Hematol. 2017 Nov;96(11):1955-1957. doi:10.1007/s00277-017-3106-7.
5. Ikeda T, Fujii H, Nose M, Kamogawa Y, Shirai T, Shirota Y, Ishii T, Harigae H. Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity. Arthritis Res Ther. 2017 Aug 11;19(1):187. doi:10.1186/s13075-017-1397-7.
6. Suzuki T, Murakami S, Biswal SS, Sakaguchi S, Harigae H, Yamamoto M, Motohashi H. Systemic Activation of NRF2 Alleviates Lethal Autoimmune Inflammation in Scurfy Mice. Mol Cell Biol. 2017 Jul 14;37(15). pii: e00063-17. doi: 10.1128/MCB.00063-17.
7. Harigae H. Biology of sideroblastic anemia. Rinsho Ketsueki. 2017;58(4):347-352. doi: 10.11406/rinketsu.58.347.
8. Fujiwara T, Sasaki K, Saito K, Hatta S, Ichikawa S, Kobayashi M, Okitsu Y, Fukuhara N, Onishi Y, Harigae H. Forced FOG1 expression in erythroleukemia cells: Induction of erythroid genes and repression of myelo-lymphoid transcription factor PU.1. Biochem Biophys Res Commun. 2017 Apr 1;485(2):380-387. doi:10.1016/j.bbrc.2017.02.068. Epub 2017 Feb 16. PubMed PMID: 28216155.
9. Inokura K, Fujiwara T, Saito K, Iino T, Hatta S, Okitsu Y, Fukuhara N, Onishi Y, Ishizawa K, Shimoda K, Harigae H. Impact of TET2 deficiency on iron metabolism in erythroblasts. Exp Hematol. 2017 May;49:56-67.e5. doi:10.1016/j.exphem.2017.01.002.
10. Nasu K, Yamaguchi K, Takanashi T, Tamai K, Sato I, Ine S, Sasaki O, Satoh K, Tanaka N, Tanaka Y, Fukushima T, Harigae H, Sugamura K. Crucial role of carbonic anhydrase IX in tumorigenicity of xenotransplanted adult T-cell leukemia-derived cells. Cancer Sci. 2017 Mar;108(3):435-443. doi: 10.1111/cas.13163.
11. Shirai T, Fujii H, Saito R, Nasu K, Kamogawa Y, Fukuhara N, Fujita Y, Shirota Y, Ishii T, Harigae H. Relapsing Polychondritis Complicated by Myelodysplastic Syndrome Is Resistant to Immunosuppression: Comment on the Article by Dion et al. Arthritis Rheumatol. 2017 Mar;69(3):682-683. doi: 10.1002/art.39969.
12. Ichikawa S, Himuro M, Okitsu Y, Fukuhara N, Watanabe M, Hatta S, Kobayashi M, Onishi Y, Matsumoto M, Harigae H. [Successful Treatment of Severe and Refractory Thrombotic Thrombocytopenic Purpura with Early Rituximab Administration]. Nihon Naika Gakkai Zasshi. 2017 Jan;106(1):99-106.
13. Yokoyama H, Takahashi N, Katsuoka Y, Inomata M, Ito T, Meguro K, Kameoka Y, Tsumanuma R, Murai K, Noji H, Ishizawa K, Ito S, Onishi Y, Harigae H; Tohoku Hematology Forum. Evaluation of the safety and efficacy of recombinant soluble thrombomodulin for patients with disseminated intravascular coagulation associated with acute leukemia: multicenter prospective study by the Tohoku Hematology Forum. Int J Hematol. 2017 May;105(5):606-613. doi:10.1007/s12185-017-2190-8.
14. Katsushima H, Fukuhara N, Konosu-Fukaya S, Himuro M, Kitawaki Y, Ichikawa S, Ishizawa K, Sasano H, Harigae H, Ichinohasama R. Does double-hit follicular lymphoma with translocations of MYC and BCL2 change the definition of transformation? Leuk Lymphoma. 2018 Mar;59(3):758-762. doi:10.1080/10428194.2017.1357172.
15. Murakami S, Suzuki T, Harigae H, Romeo PH, Yamamoto M, Motohashi H. NRF2 Activation Impairs Quiescence and Bone Marrow Reconstitution Capacity of Hematopoietic Stem Cells. Mol Cell Biol. 2017 Sep 12;37(19). pii: e00086-17. doi:10.1128/MCB.00086-17.
16. Tajima K, Takahashi N, Ishizawa K, Murai K, Akagi T, Noji H, Sasaki O, Wano M, Itoh J, Kato Y, Shichishima T, Harigae H, Ishida Y; Tohoku Hematology Forum. Clinicopathological characteristics of malignant lymphoma in patients with hepatitis C virus infection in the Tohoku district in Eastern Japan. Leuk Lymphoma. 2017 Jun;58(6):1509-1511. doi: 10.1080/10428194.2016.1236376.
17. Ishii K, Onishi Y, Miyamura N, Fukuhara N, Ishizawa K, Nakanishi M, Ohnaka S, Miyasaka T, Kanno E, Kawakami K, Harigae H, Kaku M. Development and evaluation of a quantitative assay detecting cytomegalovirus transcripts for preemptive therapy in allogeneic hematopoietic stem cell transplant recipients. J Med Virol. 2017 Jul;89(7):1265-1273. doi: 10.1002/jmv.24775.
18. Muramatsu H, Okuno Y, Yoshida K, Shiraishi Y, Doisaki S, Narita A, Sakaguchi H, Kawashima N, Wang X, Xu Y, Chiba K, Tanaka H, Hama A, Sanada M, Takahashi Y, Kanno H, Yamaguchi H, Ohga S, Manabe A, Harigae H, Kunishima S, Ishii E, Kobayashi M, Koike K, Watanabe K, Ito E, Takata M, Yabe M, Ogawa S, Miyano S, Kojima S. Clinical utility of next-generation sequencing for inherited bone marrow failure syndromes. Genet Med. 2017 Jul;19(7):796-802. doi:10.1038/gim.2016.197.
19. Kobayashi T, Nannya Y, Ichikawa M, Oritani K, Kanakura Y, Tomita A, Kiyoi H, Kobune M, Kato J, Kawabata H, Shindo M, Torimoto Y, Yonemura Y, Hanaoka N, Nakakuma H, Hasegawa D, Manabe A, Fujishima N, Fujii N, Tanimoto M, Morita Y, Matsuda A, Fujieda A, Katayama N, Ohashi H, Nagai H, Terada Y, Hino M, Sato K, Obara N, Chiba S, Usuki K, Ohta M, Imataki O, Uemura M, Takaku T, Komatsu N, Kitanaka A, Shimoda K, Watanabe K, Tohyama K, Takaori-Kondo A, Harigae H, Arai S, Miyazaki Y, Ozawa K, Kurokawa M; for National Research Group on Idiopathic Bone Marrow Failure Syndromes. A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study). Am J Hematol. 2017 Dec;92(12):1324-1332. doi: 10.1002/ajh.24905.

 

 

2016年

1. Pan X, Nariai N, Fukuhara N, Saito S, Sato Y, Katsuoka F, Kojima K, Kuroki Y, Danjoh I, Saito R, Hasegawa S, Okitsu Y, Kondo A, Onishi Y, Nagami F, Kiyomoto H, Hozawa A, Fuse N, Nagasaki M, Shimizu R, Yasuda J, Harigae H, Yamamoto M.
   Monitoring of minimal residual disease in early T-cell precursor acute lymphoblastic leukaemia by next-generation sequencing.
   Br J Haematol. 2016 Jan 29. doi: 10.1111/bjh.13948. [Epub ahead of print]
2. Ohguchi H, Hideshima T, Bhasin MK, Gorgun GT, Santo L, Cea M, Samur MK, Mimura N, Suzuki R, Tai YT, Carrasco RD, Raje N, Richardson PG, Munshi NC, Harigae H, Sanda T, Sakai J, Anderson KC.
   The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival.
   Nat Commun. 2016 Jan 5;7:10258. doi: 10.1038/ncomms10258.
3. Yoshida M1, Watanabe R1, Ishii T1, Machiyama T1, Akita K1, Fujita Y1, Shirota Y1, Sugimura K2, Fujii H1, Shimokawa H2, Harigae H1.
   Retrospective analysis of 95 patients with large vessel vasculitis: a single center experience.
   Int J Rheum Dis. 2016 Jan;19(1):87-94. doi: 10.1111/1756-185X.12777. Epub 2015 Oct 7.
4. Nakamura K, Kawakami T, Yamamoto N, Tomizawa M, Fujiwara T, Ishii T, Harigae H, Ogasawara K.
   Activation of the NLRP3 inflammasome by cellular labile iron.
   Exp Hematol. 2016 Feb;44(2):116-24. doi: 10.1016/j.exphem.2015.11.002. Epub 2015 Nov 11.
5. Harigae H1.
   [Overview].
   Rinsho Ketsueki. 2016 Feb;57(2):90. doi: 10.11406/rinketsu.57.90. Japanese.
6. Kondo A, Fujiwara T, Okitsu Y, Fukuhara N, Onishi Y, Nakamura Y, Sawada K, Harigae H.
   Identification of a novel putative mitochondrial protein FAM210B associated with erythroid differentiation.
   Int J Hematol. 2016 Apr;103(4):387-95. doi: 10.1007/s12185-016-1968-4. Epub 2016 Mar 11.
7. Sakurai K, Fujiwara T, Hasegawa S, Okitsu Y, Fukuhara N, Onishi Y, Yamada-Fujiwara M, Ichinohasama R, Harigae H.
   Inhibition of human primary megakaryocyte differentiation by anagrelide: a gene expression profiling analysis.
   Int J Hematol. 2016 Apr 15. [Epub ahead of print]
8. Katsushima H, Fukuhara N, Ichikawa S, Ota Y, Takeuchi K, Ishizawa K, Sasano H, Harigae H, Ichinohasama R.
   Non-biased and complete case registration of lymphoid leukemia and lymphoma for five years: a first representative index of Japan from an epidemiologically stable Miyagi Prefecture.
   Leuk Lymphoma. 2016 May 17:1-9. [Epub ahead of print]
9. Watanabe R, Ishii T, Araki K, Ishizuka M, Kamogawa Y, Fujita Y, Shirota Y,Fujii H, Harigae H.
   Successful multi-target therapy using corticosteroid, tacrolimus, cyclophosphamide, and rituximab for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis.
   Mod Rheumatol. 2016 May;26(3):465-6. doi: 10.3109/14397595.2015.1012797. Epub 2015 Jun 29.
10. Takahashi N, Kameoka J, Takahashi N, Tamai Y, Murai K, Honma R, Noji H, Yokoyama H, Tomiya Y, Kato Y, Ishizawa K, Ito S, Ishida Y, Sawada K, Harigae H.
    Causes of macrocytic anemia among 628 patients: mean corpuscular volumes of 114 and 130 fL as critical markers for categorization.
    Int J Hematol. 2016 Jun 28. [Epub ahead of print]
11. Onodera K, Fujiwara T, Onishi Y, Itoh-Nakadai A, Okitsu Y, Fukuhara N, Ishizawa K, Shimizu R, Yamamoto M, Harigae H.
    GATA2 regulates dendritic cell differentiation.
    Blood. 2016 Jun 3. pii: blood-2016-02-698118. [Epub ahead of print]
12. Ichikawa S, Takahashi T, Katsushima H, Fukuhara N, Ichinohasama R, Harigae H.
    Advanced Lymphocyte-rich Classical Hodgkin Lymphoma Complicated with Fatal Hemophagocytic Syndrome.
    Intern Med. 2016;55(2):191-6. doi: 10.2169/internalmedicine.55.5942. Epub 2016 Jan 15.
13. Saito S, Ishii T, Kamogawa Y, Watanabe R, Shirai T, Fujita Y, Shirota Y, Fujii H, Ito K, Shimokawa H, Yamaguchi T, Kawaguchi Y, Harigae H.
    Extracorporeal Shock Wave Therapy for Digital Ulcers of Systemic Sclerosis: A Phase 2 Pilot Study.
    Tohoku J Exp Med. 2016;238(1):39-47. doi: 10.1620/tjem.238.39.
14. Ishizuka M, Watanabe R, Ishii T, Machiyama T, Akita K, Fujita Y, Shirota Y, Fujii H, Harigae H.
    Long-term follow-up of 124 patients with polymyositis and dermatomyositis: Statistical analysis of prognostic factors.
    Mod Rheumatol. 2016;26(1):115-20. doi: 10.3109/14397595.2015.1054081. Epub 2015 Jun 13.
15. Ichikawa S, Sasaki K, Takahashi T, Hayakawa M, Matsumoto M, Harigae H.
    Thrombotic thrombocytopenic purpura associated with Klebsiella pneumonia in the background of alcoholic liver cirrhosis
    Case Rep Intern Med. 2016;3(3). doi: 10.5430/crim.v3n3p30.
16. Ono K, Murata K, Arai T, Kino T, Onaka K, Takahashi S, Sato H, Kuwahara H.
    Posterior reversible encephalopathy syndrome after iron administration in a patient with chronic severe anemia
    J Neurol Sci. 2016;367:333-334. doi: 10.1016/j.jns.2016.06.042
17. Tomiyama F, Watanabe R, Ishii T, Kamogawa Y, Fujita Y, Shirota Y, Sugimura K, Fujii H, Harigae H.
    High Prevalence of Acute Exacerbation of Interstitial Lung Disease in Japanese Patients with Systemic Sclerosis.
    Tohoku J Exp Med. 2016;239(4):297-305. doi: 10.1620/tjem.239.297.
18. Tajima K, NaotoTakahashi, Ishizawa K, Murai K, Akagi T, Noji H, Sasaki O, Wano M, Itoh J, Kato Y, Scichishima T, Ishida Y, Harigae H, Sawada K; Tohoku Hematology Forum.
    High prevalence of diffuse large B-cell lymphoma in occult hepatitis B virus-infected patients in the Tohoku district in Eastern Japan.
    J Med Virol. 2016 May 24. doi: 10.1002/jmv.24584. [Epub ahead of print]

 

 

2015年

1. Fujiwara T, Harigae H.
   【Update on the biology of heme synthesis in erythroid cells】.
   Rinsho Ketsueki. 2015 Feb;56(2):119-27. doi: 10.11406/rinketsu.56.119. Japanese.
2. Nakaseko C, Takahashi N, Ishizawa K, Kobayashi Y, Ohashi K, Nakagawa Y, Yamamoto K, Miyamura K, Taniwaki M, Okada M, Kawaguchi T, Shibata A, Fujii Y, Ono C, Ohnishi K.
   A phase 1/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia.
   Int J Hematol. 2015 Feb;101(2):154-64. doi: 10.1007/s12185-014-1722-8. 　Epub 2014 Dec 25.
3. Narumi K, Hirose T, Sato E, Mori T, Kisu K, Ishikawa M, Totsune K, Ishii T, Ichihara A, Nguyen G, Sato H, Ito S.
   A functional (pro)renin receptor is expressed in human lymphocytes and monocytes.
   Am J Physiol Renal Physiol. 2015 Mar 1;308(5):F487-99. doi: 10.1152/ajprenal.00206.2014. Epub 2014 Dec 10.
4. Harigae H.
   [Programs for Continuing Medical Education: B session; 7. Diagnosis and treatment of anemia].
   Nihon Naika Gakkai Zasshi. 2015 Mar 10;104(3):567-71.　Japanese.
5. Ichikawa S, Ichikawa S, Ishikawa I, Takahashi T, Fujiwara T, Harigae H.
   Successful treatment of acute promyelocytic leukemia with a t(X;17) (p11.4;q21) and BCOR-RARA fusion gene.
   Cancer Genet. 2015 Apr;208(4):162-3. doi: 10.1016/j.cancergen.2015.01.008. Epub 2015 Feb 2.
6. Wang J1, Shirota Y1, Bayik D1, Shirota H1, Tross D1, Gulley JL2, Wood LV3, Berzofsky JA3, Klinman DM4.
   Effect of TLR agonists on the differentiation and function of human monocytic myeloid-derived suppressor cells.
   J Immunol. 2015 May 1;194(9):4215-21. doi: 10.4049/jimmunol.1402004. Epub 2015 Mar 30.
7. Hirokawa M, Sawada K, Fujishima N, Teramura M, Bessho M, Dan K, Tsurumi H, Nakao S, Urabe A, Fujisawa S, Yonemura Y, Kawano F, Oshimi K, Sugimoto K, Matsuda A, Karasawa M, Arai A, Komatsu N, Harigae H, Omine M, Ozawa K, Kurokawa M; PRCA Collaborative Study Group.
   Long-term outcome of patients with acquired chronic pure red cell aplasia (PRCA) following immunosuppressive therapy: a final report of the nationwide cohort study in 2004/2006 by the Japan PRCA collaborative study group.
   Br J Haematol. 2015 Jun;169(6):879-86. doi: 10.1111/bjh.13376. Epub 2015 Mar 25.
8. Kameoka Y, Takahashi N, Itou S, Kume M, Noji H, Kato Y, Ichikawa Y, Sasaki O, Motegi M, Ishiguro A, Tagawa H, Ishizawa K, Ishida Y, Ichinohasama R, Harigae H, Sawada K.
   Analysis of clinical characteristics and prognostic factors for angioimmunoblastic T-cell lymphoma.
   Int J Hematol. 2015 Jun;101(6):536-42. doi: 10.1007/s12185-015-1763-7. Epub 2015 Mar 5.
9. Inui M, Hirota S, Hirano K, Fujii H, Sugahara-Tobinai A, Ishii T, Harigae H, Takai T.
   Human CD43+ B cells are closely related not only to memory B cells phenotypically but also to plasma blasts developmentally in healthy individuals.
   Int Immunol. 2015 Jul;27(7):345-55. doi: 10.1093/intimm/dxv009. Epub 2015 Mar 5.　
10. Watanabe R, Ishii T, Yoshida M, Takada N, Yokokura S, Shirota Y, Fujii H, Harigae H.
    Ulcerative keratitis in patients with rheumatoid arthritis in the modern biologic era: a series of eight cases and literature review.
    Int J Rheum Dis. 2015 Jul 14. doi: 10.1111/1756-185X.12688. [Epub ahead of print]
11. Harigae H.
    [Anemia: From Basic Knowledge to Up-to-Date Treatment. Topic: III. Iron metabolism and iron deficiency anemia--Recent findings].
    Nihon Naika Gakkai Zasshi. 2015 Jul 10;104(7):1383-8.　Japanese.
12. Saito Y, Fujiwara T, Ohashi K, Okitsu Y, Fukuhara N, Onishi Y, Ishizawa K, Harigae H.
    High-Throughput siRNA Screening to Reveal GATA-2 Upstream Transcriptional Mechanisms in Hematopoietic Cells.
    PLoS One. 2015 Sep 1;10(9):e0137079. doi: 10.1371/journal.pone.0137079. eCollection 2015.
13. Takada N, Watanabe R, Fujii H, Kamogawa Y, Fujita Y, Shirota Y, Saito S, Ishii T, Harigae H.
    Pseudothrombocytosis caused by cryoglobulin crystals in a patient with primary Sjögren's syndrome.
    Mod Rheumatol. 2015 Sep;25(5):814-5. doi: 10.3109/14397595.2014.926851. Epub 2015 Jul 29.
14. Maeda N, Ohashi T, Chagan-Yasutan H, Hattori T, Takahashi Y, Harigae H, Hasegawa H, Yamada Y, Fujii M, Maenaka K, Uede T．
    Osteopontin-integrin interaction as a novel molecular target for antibody-mediated immunotherapy in adult T-cell leukemia.
    Retrovirology. 2015 Nov 24;12:99. doi: 10.1186/s12977-015-0225-x.
15. Murai K, Akagi T, Shimosegawa K, Sugawara T, Ishizawa K, Ito S, Murai K, Motegi M, Yokoyama H, Noji H, Tajima K, Kimura J, Chou T, Ogawa K, Harigae H, Kubo K, Oba K, Sakamoto J, Ishida Y.
    A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.
    Eur J Haematol. 2015 Dec;95(6):558-65. doi: 10.1111/ejh.12536. Epub 2015 Mar 25.　　　　
16. Tomiyama F, Watanabe R, Fujii H, Kamogawa Y, Fujita Y, Shirota Y, Nakamichi T, Sato H, Ishii T, Harigae H.
    Synovitis in a Patient with IgG4-related Disease.
    Intern Med. 2015;54(11):1427-32. doi: 10.2169/internalmedicine.54.4320. Epub 2015 Jun 1.
17. Fujiwara T, Harigae H.
    Biology of Heme in Mammalian Erythroid Cells and Related Disorders.
    Biomed Res Int. 2015;2015:278536. doi: 10.1155/2015/278536. Epub 2015 Oct 18
18. Watanabe R, Ishii T, Harigae H.
    Pretreatment Screening for Hepatitis B Virus Infection in Patients with Systemic Lupus Erythematosus.
    Tohoku J Exp Med. 2015;237(1):9-15. doi: 10.1620/tjem.237.9.
19. Watanabe R, Fujii H, Kamogawa Y, Nakamura K, Shirai T, Ishii T, Harigae H.
    Chronic lupus peritonitis is characterized by the ascites with a large content of interleukin-6.
    Tohoku J Exp Med. 2015;235(4):289-94. doi: 10.1620/tjem.235.289.

 

 

2014年

1. Kaneko K, Furuyama K, Fujiwara T, Kobayashi R, Ishida H, Harigae H, Shibahara S.
   Identification of a novel erythroid-specific enhancer for the ALAS2 gene and its loss-of-function mutation which is associated with congenital sideroblastic anemia.
   Haematologica. 2014 Feb;99(2):252-61. doi: 10.3324/haematol.2013.085449. Epub 2013 Aug 9.
2. Watanabe R, Ishii T, Nakamura K, Shirai T, Fujii H, Saito S, Harigae H.
   Ulcerative colitis is not a rare complication of Takayasu arteritis.
   Mod Rheumatol. 2014 Mar;24(2):372-3. doi: 10.3109/14397595.2013.854045.
3. Fujiwara T, Saitoh H, Inoue A, Kobayashi M, Okitsu Y, Katsuoka Y, Fukuhara N, Onishi Y, Ishizawa K, Ichinohasama R, Harigae H.
   3-Deazaneplanocin A (DZNep), an inhibitor of S-adenosylmethionine-dependent methyltransferase, promotes erythroid differentiation.
   J Biol Chem. 2014 Mar 21;289(12):8121-34. doi: 10.1074/jbc.M114.548651. Epub 2014 　Feb 3.
4. Kato H, Onishi Y, Nakajima S, Okitsu Y, Fukuhara N, Fujiwara T, Yamada-Fujiwara M, Kameoka J, Ishizawa K, Harigae H.
   Significant improvement of Takayasu arteritis after cord blood transplantation in a patient with myelodysplastic syndrome.
   Bone Marrow Transplant. 2014 Mar;49(3):458-9. doi: 10.1038/bmt.2013.198. Epub 2013 Dec 9.
5. Takahashi N, Miura M, Kuroki J, Mitani K, Kitabayashi A, Sasaki O, Kimura H, Imai K, Tsukamoto N, Noji H, Kondo T, Motegi M, Kato Y, Mita M, Saito H, Yoshida C, Torimoto Y, Kimura T, Wano Y, Nomura J, Yamamoto S, Mayama K, Honma R, Sugawara T, Sato S, Shinagawa A, Abumiya M, Niioka T, Harigae H, Sawada K.
   Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib.
   Biomark Res. 2014 Mar 20;2(1):6. doi: 10.1186/2050-7771-2-6.
6. Watanabe R, Fujii H, Shirai T, Saito S, Hatakeyama A, Sugimura K, Fukumoto Y, Ishii T, Harigae H.
   Successful use of intensive immunosuppressive therapy for treating simultaneously occurring cerebral lesions and pulmonary arterial hypertension in a patient with systemic lupus erythematosus.
   Intern Med. 2014;53(6):627-31.
7. Watanabe R, Fujii H, Ishii T, Harigae H.
   Calcified iliopsoas abscess caused by Enterococcus faecalis.
   Intern Med. 2014;53(4):345.
8. Ichikawa S, Fukuhara N, Katsushima H, Takahashi T, Yamamoto J, Yokoyama H, Sasaki O, Fukuhara O, Nomura J, Ishizawa K, Ichinohasama R, Muto A, Igarashi K, Harigae H
   Association between BACH2 expression and clinical prognosis in diffuse large B-cell lymphoma.
   Cancer Sci. 2014 Apr;105(4):437-44. doi: 10.1111/cas.12361. Epub 2014 Mar 8.
9. Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R.
   Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
   J Clin Oncol. 2014 Apr 10;32(11):1157-63. doi: 10.1200/JCO.2013.52.0924. Epub 2014 Mar 10.
10. Ogura M, Ando K, Suzuki T, Ishizawa K, Oh SY, Itoh K, Yamamoto K, Au WY, Tien HF, Matsuno Y, Terauchi T, Yamamoto K, Mori M, Tanaka Y, Shimamoto T, Tobinai K, Kim WS.
    A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
    Br J Haematol. 2014 Jun;165(6):768-76. doi: 10.1111/bjh.12819. Epub 2014 Mar 12.
11. Harigae H.
    [Recent progress of diagnosis and treatment for immune-mediated hematological diseases. Editorial: Immune-mediated hematological diseases].
    Nihon Naika Gakkai Zasshi. 2014 Jul 10;103(7):1561-3. Japanese.
12. Harigae H, Fujiwara T, Furuyama K.
    [Heme metabolism and anemia].
    Rinsho Ketsueki. 2014 Jul;55(7):729-34. Japanese.
13. Sampei S, Watanabe R, Ishii T, Harigae H.
    Granulomatosis with polyangiitis preceded by central diabetes insipidus.
    Intern Med. 2014;53(15):1725-6. Epub 2014 Aug 1.
14. Ogura M, Tobinai K, Hatake K, Ishizawa K, Uike N, Uchida T, Suzuki T, Aoki T, Watanabe T, Maruyama D, Yokoyama M, Takubo T, Kagehara H, Matsushima T.
    Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.
    Cancer Sci. 2014 Jul;105(7):840-6. doi: 10.1111/cas.12435. Epub 2014 Jul 1.　
15. Ishii T.
    [Recent progress of diagnosis and treatment for immune-mediated hematological diseases. Topics: II. Differential diagnosis; 2. Cytopenia in connective tissue disease].
    Nihon Naika Gakkai Zasshi. 2014 Jul 10;103(7):1586-92. Japanese
16. Kanehira M, Kikuchi T, Santoso A, Tode N, Hirano T, Ohkouchi S, Tamada T, Sugiura H, Harigae H, Ichinose M.
    Human marrow stromal cells downsize the stem cell fraction of lung cancers by fibroblast growth factor 10.
    Mol Cell Biol. 2014 Aug;34(15):2848-56. doi: 10.1128/MCB.00871-13. Epub 2014 May 27.
17. Watanabe R, Fujii H, Shirai T, Saito S, Ishii T, Harigae H.
    Autophagy plays a protective role as an anti-oxidant system in human T cells and represents a novel strategy for induction of T-cell apoptosis.
    Eur J Immunol. 2014 Aug;44(8):2508-20. doi: 10.1002/eji.201344248. Epub 2014 Jun 16.
18. Fujiwara T, Fukuhara N, Funayama R, Nariai N, Kamata M, Nagashima T, Kojima K, Onishi Y, Sasahara Y, Ishizawa K, Nagasaki M, Nakayama K, Harigae H.
    Identification of acquired mutations by whole-genome sequencing in GATA-2 deficiency evolving into myelodysplasia and acute leukemia.
    Ann Hematol. 2014 Sep;93(9):1515-22. doi: 10.1007/s00277-014-2090-4. Epub 2014 Apr 30.
    
19. Onishi Y, Sugimura K, Ohba R, Imadome K, Shimokawa　H, Harigae H.
    Resolution of chronic active EBV infection and coexisting pulmonary arterial hypertension after cord blood transplantation.
    Bone Marrow Transplant. 2014 Oct;49(10):1343-4. doi: 10.1038/bmt.2014.129. Epub 2014 Jun 23.
20. Yamaki S, Ine S, Kawabe T, Okuyama Y, Suzuki N, Soroosh P, Mousavi SF, Nagashima H, Sun SL, So T, Sasaki T, Harigae H, Sugamura K, Kudo H, Wada M, Nio M, Ishii N.
    OX40 and IL-7 play synergistic roles in the homeostatic proliferation of effector memory CD4⁺ T cells.
    Eur J Immunol. 2014 Oct;44(10):3015-25. doi: 10.1002/eji.201444701. Epub 2014 Sep 18.
21. Fujiwara T, Okamoto K, Niikuni R, Takahashi K, Okitsu Y, Fukuhara N, Onishi Y, Ishizawa K, Ichinohasama R, Nakamura Y, Nakajima M, Tanaka T, Harigae H.
    Effect of 5-aminolevulinic acid on erythropoiesis: a preclinical in vitro characterization for the treatment of congenital sideroblastic anemia.
    Biochem Biophys Res Commun. 2014 Nov 7;454(1):102-8. doi: 0.1016/j.bbrc.2014.10.050. Epub 2014 Oct 18.
22. Kamata M, Okitsu Y, Fujiwara T, Kanehira M, Nakajima S, Takahashi T, Inoue A, Fukuhara N, Onishi Y, Ishizawa K, Shimizu R, Yamamoto M, Harigae H
    GATA2 regulates differentiation of bone marrow-derived mesenchymal stem cells.
    Haematologica. 2014 Nov;99(11):1686-96. doi: 10.3324/haematol.2014.105692. Epub 2014 Aug 22.
23. Ichikawa S, Kim M, Hasegawa S, Ohashi K, Kondo A, Kato H, Kamata M, Okitsu Y, Fukuhara N, Onishi Y, Ishizawa K, Harigae H.
    Fatal visceral varicella-zoster developing early after autologous hematopoietic stem cell transplantation for refractory diffuse large B-cell lymphoma.
    J Clin Exp Hematop. 2014;54(3):237-41.
24. Nakajima S, Fujiwara T, Ohguchi H, Onishi Y, Kamata M, Okitsu Y, Fukuhara N, Ishizawa K, Harigae H.
    Induction of thymic stromal lymphopoietin in mesenchymal stem cells by interaction with myeloma cells.
    Leuk Lymphoma. 2014 Nov;55(11):2605-13. doi: 10.3109/10428194.2014.881478. Epub 2014 Mar 7
25. Watanabe R, Hirabayashi Y, Okuno H, Ishii T, Harigae H.
    Dramatic radiographic repair by tocilizumab in a very elderly patient with rheumatoid arthritis.
    Mod Rheumatol. 2014 Nov;24(6):1028-9. doi: 10.3109/14397595.2013.844395. Epub 2013 Oct 21.
26. Suzuki T, Kawamoto S, Kumagai K, Adachi O, Kanda K, Ishikawa M, Okitsu Y, Harigae H, Kurosawa S, Saiki Y.
    Coronary artery bypass grafting in a patient with hemophilia B: continuous recombinant factor IX infusion as per the Japanese guidelines for replacement therapy.
    Gen Thorac Cardiovasc Surg. 2014 Dec 19. [Epub ahead of print]
27. Watanabe R, Ishii T, Kobayashi H, Asahina I, Takemori H, Izumiyama T, Oguchi Y, Urata Y, Nishimaki T, Chiba K, Komatsuda A, Chiba N, Miyata M, Takagi M, Kawamura O, Kanno T, Hirabayashi Y, Konta T, Ninomiya Y, Abe Y, Murata Y, Saito Y, Ohira H, Harigae H, Sasaki T.
    Prevalence of hepatitis B virus infection in patients with rheumatic diseases in Tohoku area: a retrospective multicenter survey.
    Tohoku J Exp Med. 2014;233(2):129-33.
28. Kawakami Y, Endo K, Ishii T, Haneda S, Fujishima F, Kakuta Y, Shiga H, Kinouchi Y, Shimosegawa T.
    Ileocecal ulcers accompanied by relapsing polychondritis: a case report.
    Springerplus. 2014 Dec 7;3:714. doi: 10.1186/2193-1801-3-714. eCollection 2014.

 

 

2013年

1. Fujiwara T, Ikeda T, Nagasaka Y, Okitsu Y, Katsuoka Y, Fukuhara N, Onishi Y, Ishizawa K, Ichinohasama R, Tomosugi N, Harigae H.
   A low-molecular-weight compound K7174 represses hepcidin: possible therapeutic strategy against anemia of chronic disease.
   PLoS One. 2013 Sep 27;8(9):e75568. doi: 10.1371/journal.pone.0075568. eCollection 2013.
2. Fujiwara T, Alqadi YW, Okitsu Y, Fukuhara N, Onishi Y, Ishizawa K, Harigae H.
   Role of transcriptional corepressor ETO2 in erythroid cells.
   Exp Hematol. 2013 Mar;41(3):303-15.e1. doi: 10.1016/j.exphem.2012.10.015.
3. Fujiwara T, Okitsu Y, Katsuoka Y, Fukuhara N, Onishi Y, Ishizawa K, Harigae H.
   Expression profiling of ETO2-regulated miRNAs in erythroid cells: Possible influence on miRNA abundance.
   FEBS Open Bio. 2013 Oct 11;3:428-32. doi: 10.1016/j.fob.2013.10.004. eCollection 2013.
4. Fujiwara T, Harigae H.
   Pathophysiology and genetic mutations in congenital sideroblastic anemia.
   Pediatr Int. 2013 Sep 4. doi: 10.1111/ped.12217. [Epub ahead of print]
5. Ichikawa S, Fukuhara N, Inoue A, Katsushima H, Ohba R, Katsuoka Y, Onishi Y, Yamamoto J, Sasaki O, Nomura J, Fukuhara O, Ishizawa K, Ichinohasama R, Harigae H.
   Clinicopathological analysis of primary adrenal diffuse large B-cell lymphoma: effectiveness of rituximab-containing chemotherapy including central nervous system prophylaxis.
   Exp Hematol Oncol. 2013 Aug 2;2(1):19. doi: 10.1186/2162-3619-2-19.6.
6. Ichikawa S, Watanabe Y, Saito K, Kimura J, Ichinohasama R, Harigae H.
   T-cell/histiocyte-rich large B-cell lymphoma of the thyroid.
   Exp Hematol Oncol. 2013 Jan 9;2(1):1. doi: 10.1186/2162-3619-2-1.
7. Ichikawa S, Saito K, Suzuki T, Kimura J, Harigae H.
   Primary Retroperitoneal Diffuse Large B-cell Lymphoma Presenting with Numb Chin Syndrome and Painful Ophthalmoplegia.
   Intern Med. 2013;52(16):1813-9.
8. Inoue A, Fujiwara T, Okitsu Y, Katsuoka Y, Fukuhara N, Onishi Y, Ishizawa K, Harigae H.
   Elucidation of the role of LMO2 in human erythroid cells.
   Exp Hematol. 2013 Sep 13. doi:pii: S0301-472X(13)00706-6. 10.1016/j.exphem.2013.09.003. [Epub ahead of print]
9. Kato H, Onishi Y, Okitsu Y, Katsuoka Y, Fujiwara T, Fukuhara N, Ishizawa K, Takagawa M, Harigae H.
   Addition of clarithromycin to lenalidomide/low-dose dexamethasone was effective in a case of relapsed myeloma after long-term use of lenalidomide.
   Ann Hematol. 2013 Apr 28. [Epub ahead of print]
10. Nakamura K, Nakayama M, Kawano M, Amagai R, Ishii T, Harigae H, Ogasawara K.
    Fratricide of natural killer cells dressed with tumor-derived NKG2D ligand.
    Proc Natl Acad Sci U S A. 2013 Jun 4;110(23):9421-6. doi: 10.1073/pnas.1300140110. Epub 2013 May 20.
11. Ohba R, Furuyama K, Yoshida K, Fujiwara T, Fukuhara N, Onishi Y, Manabe A, Ito E, Ozawa K, Kojima S, Ogawa S, Harigae H.
    Clinical and genetic characteristics of congenital sideroblastic anemia: comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS).
    Ann Hematol. 2013 Jan;92(1):1-9. doi: 10.1007/s00277-012-1564-5. Epub 2012 Sep 16.
12. Shirai T, Fujii H, Ono M, Watanabe R, Ishii T, Harigae H.
    An innovative method to identify autoantigens expressed on the endothelial cell surface: serological identification system for autoantigens using a retroviral vector and flow cytometry (SARF).
    Clin Dev Immunol. 2013;2013:453058. doi: 10.1155/2013/453058. Epub 2013 Jan 16. Review.
13. Shirai T, Fujii H, Ono M, Watanabe R, Shirota Y, Saito S, Ishii T, Nose M, Harigae H.
    A novel autoantibody against ephrin type B receptor 2 in acute necrotizing encephalopathy.
    J Neuroinflammation. 2013 Oct 18;10:128. doi: 10.1186/1742-2094-10-128.
14. Shirai T, Fujii H, Saito S, Ishii T, Yamaya H, Miyagi S, Sekiguchi S, Kawagishi N, Nose M, Harigae H.
    Polyarteritis nodosa clinically mimicking nonocclusive mesenteric ischemia.
    World J Gastroenterol. 2013 Jun 21;19(23):3693-8. doi: 10.3748/wjg.v19.i23.3693.
15. Watanabe R, Ishii T, Nakamura K, Shirai T, Fujii H, Saito S, Harigae H.
    Ulcerative colitis is not a rare complication of Takayasu arteritis.
    Mod Rheumatol. 2013 Jan 18. [Epub ahead of print] No abstract available.
16. Yang Z, Fujii H, Mohan SV, Goronzy JJ, Weyand CM.
    Phosphofructokinase deficiency impairs ATP generation, autophagy, and redox balance in rheumatoid arthritis T cells.
    J Exp Med. 2013 Sep 16. [Epub ahead of print]
17. Kaneko K, Furuyama K, Fujiwara T, Kobayashi R, Ishida H, Harigae H, Shibahara S.
    Identification of the novel erythroid-specific enhancer for ALAS2 gene and its loss-of-function mutation associated with congenital sideroblastic anemia.
    Haematologica. 2013 Aug 9. [Epub ahead of print]
18. Ogura M, Itoh K, Ishizawa K, Kobayashi Y, Tobinai K, Kinoshita T, Hirano M, Ueda R, Shibata T, Nakamura S, Tsukasaki K, Hotta T, Shimoyama M, Morishima Y; the members of the Lymphoma Study Group of JCOG (JCOG-LSG).
    Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705).
    Leuk Lymphoma. 2013 Jan;54(1):46-52. doi: 10.3109/10428194.2012.705000.
19. Shimane K, Kochi Y, Suzuki A, Okada Y, Ishii T, Horita T, Saito K, Okamoto A, Nishimoto N, Myouzen K, Kubo M, Hirakata M, Sumida T, Takasaki Y, Yamada R, Nakamura Y, Kamatani N, Yamamoto K.
    An association analysis of HLA-DRB1 with systemic lupus erythematosus and rheumatoid arthritis in a Japanese population: effects of *09:01 allele on disease phenotypes.
    Rheumatology (Oxford). 2013 Feb 12. [Epub ahead of print]
20. Takata K, Sato Y, Nakamura N, Tokunaka M, Miki Y, Yukie Kikuti Y, Igarashi K, Ito E, Harigae H, Kato S, Hayashi E, Oka T, Hoshii Y, Tari A, Okada H, Al-Kader LA, Maeda Y, Tanimoto M, Kinoshita T, Yoshino T.
    Duodenal follicular lymphoma lacks AID but expresses BACH2 and has memory B-cell characteristics.
    Mod Pathol. 2013 Jan;26(1):22-31. doi: 10.1038/modpathol.2012.127.

 

 

2012年

1. Fujiwara T, Yokoyama H, Okitsu Y, Kamata M, Fukuhara N, Onishi Y, Fujimaki S, Takahashi S, Ishizawa K, Bresnick EH, Harigae H.
   Gene expression profiling identifies HOXB4 as a direct downstream target of GATA-2 in human CD34+ hematopoietic cells.
   PLoS One. 2012;7(9):e40959. doi: 10.1371/journal.pone.0040959.
2. Ichikawa S, Suzuki T, Kimura J, Harigae H.
   Successful treatment of acute promyelocytic leukemia accompanied by serious subdural hematoma.
   Intern Med. 2012;51(16):2209-12.
3. Ichikawa S, Hatta S, Saito Y, Kimura J, Onishi K, Matsuda M, Ichinohasama R, Harigae H.
   CD20-positive and CD4/CD8-double-negative peripheral T-cell lymphoma of spleen complicated with severe disseminated intravascular coagulation and enteropathy.
   J Clin Exp Hematop. 2012;52(2):133-6.
4. Inokura K, Onishi Y, Shimosegawa K, Okitsu Y, Katsuoka Y, Fujiwara T, Fukuhara N, Ishizawa K, Harigae H.
   Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor.
   Ann Hematol. 2012 Nov;91(11):1825-6. doi: 10.1007/s00277-012-1477-3.
5. Yamada-Fujiwara M, Miyamura K, Fujiwara T, Tohmiya Y, Endo K, Onishi Y, Ishizawa K, Kameoka J, Ito M, Harigae H.
   Diagnosis of intestinal graft-versus-host disease and thrombotic microangiopathy after allogeneic stem cell transplantation.
   Tohoku J Exp Med. 2012;227(1):31-7.
6. Kameoka J, Takahashi N, Noji H, Murai K, Tajima K, Kameoka Y, Sato S, Shichishima T, Ishida Y, Harigae H, Sawada K.
   T-cell prolymphocytic leukemia in Japan: is it a variant?
   Int J Hematol. 2012 Jun;95(6):660-7. doi: 10.1007/s12185-012-1077-y.
   
7. Shirai T, Fujii H, Ono M, Nakamura K, Watanabe R, Tajima Y, Takasawa N, Ishii T, Harigae H.
   A novel autoantibody against fibronectin leucine-rich transmembrane protein 2 expressed on the endothelial cell surface identified by retroviral vector system in systemic lupus erythematosus.
   Arthritis Res Ther. 2012 Jul 2;14(4):R157.
8. Suzuki M, Takahashi T, Katano I, Ito R, Ito M, Harigae H, Ishii N, Sugamura K.
   Induction of human humoral immune responses in a novel HLA-DR-expressing transgenic NOD/Shi-scid/γcnull mouse.
   Int Immunol. 2012 Apr;24(4):243-52. doi: 10.1093/intimm/dxs045.
   
9. Watanabe R, Ishii T, Nakamura K, Shirai T, Tajima Y, Fujii H, Harigae H.
   Prevalence and time course of hepatitis B virus infection in patients with systemic lupus erythematosus under immunosuppressive therapy.
   Mod Rheumatol. 2012 Nov 21. [Epub ahead of print]
10. Fujiwara T.
    [Genome-wide analysis of GATA transcription factor in hematopoietic cells].
    Rinsho Ketsueki. 2012 Mar;53(3):287-94. Review. Japanese.
11. Harigae H.
    [109th Scientific Meeting of the Japanese Society of Internal medicine: symposium: 1. Recent treatments and progress in malignant tumors--chemotherapy and molecular targeting agents. Antibody therapy; 4) Progress and diversification in treatment for hematological malignancies].
    Nihon Naika Gakkai Zasshi. 2012 Sep 10;101(9):2526-31. Japanese.
12. Aoyama S, Nakano H, Danbara M, Higashihara M, Harigae H, Takahashi S.
    The differentiating and apoptotic effects of 2-aza-5'-deoxycytidine are dependent on the PU.1 expression level in PU.1-transgenic K562 cells.
    Biochem Biophys Res Commun. 2012 Apr 20;420(4):775-81. doi: 10.1016/j.bbrc.2012.03.071.
    
13. Harigai M, Tanaka Y, Maisawa S; JA21963 Study Group.
    Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: a placebo-controlled double-blind parallel-group study.
    J Rheumatol. 2012 Mar;39(3):486-95. doi: 10.3899/jrheum.110994.
14. Iseki Y, Nakahara M, Kubo M, Obata F, Harigae H, Takahashi S.
    Correlation of PU.1 and signal regulatory protein α1 expression in PU.1 transgenic K562 cells.
    Int J Mol Med. 2012 Feb;29(2):319-23. doi: 10.3892/ijmm.2011.827.
15. Kadirvel S, Furuyama K, Harigae H, Kaneko K, Tamai Y, Ishida Y, Shibahara S.
    The carboxyl-terminal region of erythroid-specific 5-aminolevulinate synthase acts as an intrinsic modifier for its catalytic activity and protein stability.
    Exp Hematol. 2012 Jun;40(6):477-86.e1. doi: 10.1016/j.exphem.2012.01.013.
16. Kameoka Y, Takahashi N, Ishizawa K, Kato Y, Ito J, Sasaki O, Murai K, Noji H, Hirokawa M, Tajima K, Shichishima T, Ishida Y, Harigae H, Sawada K.
    Safety and feasibility of high-dose ranimustine (MCNU), carboplatin, etoposide, and cyclophosphamide (MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma.
    Int J Hematol. 2012 Nov;96(5):624-30. doi: 10.1007/s12185-012-1186-7.
17. Okada Y, Shimane K, Kochi Y, Tahira T, Suzuki A, Higasa K, Takahashi A, Horita T, Atsumi T, Ishii T, Okamoto A, Fujio K, Hirakata M, Amano H, Kondo Y, Ito S, Takada K, Mimori A, Saito K, Kamachi M, Kawaguchi Y, Ikari K, Mohammed OW, Matsuda K, Terao C, Ohmura K, Myouzen K, Hosono N, Tsunoda T, Nishimoto N, Mimori T, Matsuda F, Tanaka Y, Sumida T, Yamanaka H, Takasaki Y, Koike T, Horiuchi T, Hayashi K, Kubo M, Kamatani N, Yamada R, Nakamura Y, Yamamoto K.
    A genome-wide association study identified AFF1 as a susceptibility locus for systemic lupus eyrthematosus in Japanese.
    PLoS Genet. 2012 Jan;8(1):e1002455. doi: 10.1371/journal.pgen.1002455.
18. Tagami K, Tanda S, Kato H, Tashiro A, Saji K, Komaru T, Tanida M, Nakura H, Ishizawa K.
    Detection of asymptomatic cardiac metastasis and successful salvage chemotherapy comprising a prednisone, Etoposide, procarbazine, and cyclophosphamide regimen in an elderly Japanese patient suffering from a delayed recurrence of diffuse large B-cell lymphoma.
    Case Rep Oncol. 2012 Jan;5(1):62-8. doi: 10.1159/000336447.
19. Takata K, Sato Y, Nakamura N, Tokunaka M, Miki Y, Yukie Kikuti Y, Igarashi K, Ito E, Harigae H, Kato S, Hayashi E, Oka T, Hoshii Y, Tari A, Okada H, Mohamad AA, Maeda Y, Tanimoto M, Kinoshita T, Yoshino T.
    Duodenal follicular lymphoma lacks AID but expresses BACH2 and has memory B-cell characteristics.
    Mod Pathol. 2013 Jan;26(1):22-31. doi: 10.1038/modpathol.2012.127.
20. Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, Ishizawa K, Maseki N, Itoh K, Usui N, Wasada I, Kinoshita T, Hotta T, Tsukasaki K, Oshimi K.
    Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: An Updated Analysis of the Japan Clinical Oncology Group Study JCOG0211.
    J Clin Oncol. 2012 Nov 10;30(32):4044-6. doi: 10.1200/JCO.2012.45.6541.

 

 

2011年

1. Miura Y, Fukuhara N, Yamamoto J, Kohata K, Ishizawa K, Ichinohasama R, Harigae H.
   Clinicopathological features of malignant lymphoma in Japan: the Miyagi Study.
   Tohoku J Exp Med. 2011;224(2):151-60.
2. Ohguchi H, Ohba R, Onishi Y, Fukuhara N, Okitsu Y, Yamamoto J, Ishizawa K, Ichinohasama R, Harigae H.
   Successful treatment with bortezomib and thalidomide for POEMS syndrome.
   Ann Hematol. 2011 Sep;90(9):1113-4. doi: 10.1007/s00277-010-1133-8.
3. Oka Y, Hirabayashi Y, Ikeda T, Fujii H, Ishii T, Harigae H.
   A single-stranded DNA-cross-reactive immunogenic epitope of human homocysteine-inducible endoplasmic reticulum protein.
   Scand J Immunol. 2011 Sep;74(3):296-303. doi: 10.1111/j.1365-3083.2011.02572.x.
4. Onishi Y, Sasaki O, Ichikawa S, Inokura K, Katsuoka Y, Ohtsuka Ohba R, Okitsu Y, Kohata K, Ohguchi H, Fukuhara N, Yokoyama H, Yamada MF, Yamamoto J, Ishizawa K, Kameoka J, Harigae H.
   Favorable outcome of unrelated cord blood transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
   Biol Blood Marrow Transplant. 2011 Jul;17(7):1093-7. doi: 10.1016/j.bbmt.2011.01.010.
5. Shirai T, Ishii T, Watanabe R, Tajima Y, Fujii H, Takasawa N, Sato H, Harigae H.
   Thrombotic microangiopathy presenting with a considerable accumulation of ascites: a case report.
   Intern Med. 2011;50(1):53-7.
6. Yamamoto J, Fujishima F, Ichinohasama R, Imatani A, Asano N, Harigae H.
   A case of benign natural killer cell proliferative disorder of the stomach (gastric manifestation of natural killer cell lymphomatoid gastroenteropathy) mimicking extranodal natural killer/T-cell lymphoma.
   Leuk Lymphoma. 2011 Sep;52(9):1803-5. doi: 10.3109/10428194.2011.573030.
7. Harigae H.
   [Recent progress in iron metabolism and iron-related anemia].
   Rinsho Byori. 2010 Dec;58(12):1211-8. Review. Japanese.
8. Ohguchi H, Okitsu Y, Kobayashi M, Yokoyama H, Suzuki S, Ishikawa M, Oba R, Yamamoto J, Isizawa K, Harigae H.
   [Case report; acquired factor V inhibitor with hemoptysis and hematuria].
   Nihon Naika Gakkai Zasshi. 2011 Jan 10;100(1):182-4. Japanese.
9. Seki M, Sugawara T, Yamamoto K, Takahashi T, Harigae H.
   [A case of intravascular large B-cell lymphoma associated with transverse myelopathy].
   Gan To Kagaku Ryoho. 2011 Nov;38(11):1885-8. Japanese.
10. Akagi T, Takahashi N, Yamaguchi K, Ishizawa K, Murai K, Tajima K, Ikeda K, Kameoka Y, Kameoka J, Ito S, Kato Y, Noji H, Shichishima T, Itoh J, Ichinohasama R, Harigae H, Ishida Y, Sawada K.
    Comparison of long-term clinical outcomes of CHOP chemotherapy between Japanese patients with nodal peripheral T-cell lymphomas and those with diffuse large B-cell lymphoma in the study group of the Tohoku Hematology Forum.
    J Clin Exp Hematop. 2011;51(1):29-35.
11. Chagan-Yasutan H, Tsukasaki K, Takahashi Y, Oguma S, Harigae H, Ishii N, Zhang J, Fukumoto M, Hattori T.
    Involvement of osteopontin and its signaling molecule CD44 in clinicopathological features of adult T cell leukemia.
    Leuk Res. 2011 Nov;35(11):1484-90. doi: 10.1016/j.leukres.2011.05.011.
12. Kobayashi Y, Sakamaki H, Fujisawa S, Ando K, Yamamoto K, Okada M, Ishizawa K, Nagai T, Miyawaki S, Motoji T, Usui N, Iida S, Taniwaki M, Uoshima N, Seriu T, Ohno R.
    Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis.
    Int J Hematol. 2011 Jun;93(6):745-9. doi: 10.1007/s12185-011-0864-1.
13. Kudo Y, Minegishi M, Seki O, Takahashi H, Suzuki A, Narita A, Sato Y, Abe M, Ishioka N, Harigae H, Tsuchiya S.
    Quality assessment of umbilical cord blood units at the time of transplantation.
    Int J Hematol. 2011 May;93(5):645-51. doi: 10.1007/s12185-011-0830-y.
14. Minami Y, Hirabayashi Y, Nagata C, Ishii T, Harigae H, Sasaki T.
    Intakes of vitamin B6 and dietary fiber and clinical course of systemic lupus erythematosus: a prospective study of Japanese female patients.
    J Epidemiol. 2011;21(4):246-54.
15. Miyamichi-Yamamoto S, Fukumoto Y, Sugimura K, Ishii T, Satoh K, Miura Y, Tatebe S, Nochioka K, Aoki T, Do E Z, Shimokawa H.
    Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease.
    Circ J. 2011;75(11):2668-74. Epub 2011 Aug 27.
16. Ogura M, Ando K, Taniwaki M, Watanabe T, Uchida T, Ohmachi K, Matsumoto Y, Tobinai K; Japanese Bendamustine Lymphoma Study Group.
    Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
    Cancer Sci. 2011 Sep;102(9):1687-92. doi: 10.1111/j.1349-7006.2011.01994.x.
17. Tateishi U, Tatsumi M, Terauchi T, Ishizawa K, Ogura M, Tobinai K.
    Relevance of monitoring metabolic reduction in patients with relapsed or refractory follicular and mantle cell lymphoma receiving bendamustine: a multicenter study.
    Cancer Sci. 2011 Feb;102(2):414-8. doi: 10.1111/j.1349-7006.2010.01802.x.
18. Uruno A, Noguchi N, Matsuda K, Nata K, Yoshikawa T, Chikamatsu Y, Kagechika H, Harigae H, Ito S, Okamoto H, Sugawara A.
    All-trans retinoic acid and a novel synthetic retinoid tamibarotene (Am80) differentially regulate CD38 expression in human leukemia HL-60 cells: possible involvement of protein kinase C-delta.
    J Leukoc Biol. 2011 Aug;90(2):235-47. doi: 10.1189/jlb.0109025.

 

 

2010年

1. Fujiwara T, Lee HY, Sanalkumar R, Bresnick EH.
   Building multifunctionality into a complex containing master regulators of hematopoiesis.
   Proc Natl Acad Sci U S A. 2010 Nov 23;107(47):20429-34. doi: 10.1073/pnas.1007804107. Epub 2010 Nov 8.
2. Fujiwara T, O'Geen H, Keles S, Blahnik K, Linnemann AK, Kang YA, Choi K, Farnham PJ, Bresnick EH.
   Discovering hematopoietic mechanisms through genome-wide analysis of GATA factor chromatin occupancy.
   Mol Cell. 2009 Nov 25;36(4):667-81. doi: 10.1016/j.molcel.2009.11.001.
3. Harigae H, Furuyama K.
   Hereditary sideroblastic anemia: pathophysiology and gene mutations.
   Int J Hematol. 2010 Oct;92(3):425-31. doi: 10.1007/s12185-010-0688-4.
4. Hirabayashi Y, Oka Y, Ikeda T, Fujii H, Ishii T, Sasaki T, Harigae H.
   The endoplasmic reticulum stress-inducible protein, Herp, is a potential triggering antigen for anti-DNA response.
   J Immunol. 2010 Mar 15;184(6):3276-83. doi: 10.4049/jimmunol.0900670.
5. Ichikawa S, Fukuhara N, Yamamoto J, Suzuki M, Nakajima S, Okitsu Y, Kohata K, Onishi Y, Ishizawa K, Kameoka J, Harigae H.
   Successful allogeneic hematopoietic stem cell transplantation for aggressive NK cell leukemia.
   Intern Med. 2010;49(17):1907-10.
6. Ichinohasama R, Oji Y, Yokoyama H, Takeuchi K, Fujiwara T, Ishizawa K, Taniguchi O, Tsuboi A, Oka Y, Sugiyama H.
   Sensitive immunohistochemical detection of WT1 protein in tumors with anti-WT1 antibody against WT1 235 peptide.
   Cancer Sci. 2010 May;101(5):1089-92. doi: 10.1111/j.1349-7006.2010.01522.x.
7. Irie E, Shirota Y, Suzuki C, Tajima Y, Ishizawa K, Kameoka J, Harigae H, Ishii T.
   Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis.
   Int J Hematol. 2010 Apr;91(3):501-8. doi: 10.1007/s12185-010-0528-6. Epub 2010 Mar 10.
8. Kato H, Kohata K, Yamamoto J, Ichikawa S, Watanabe M, Ishizawa K, Ichinohasama R, Harigae H.
   Extreme eosinophilia caused by interleukin-5-producing disseminated colon cancer.
   Int J Hematol. 2010 Mar;91(2):328-30. doi: 10.1007/s12185-010-0491-2.
9. Shirai T, Hirabayashi Y, Watanabe R, Tajima Y, Fujii H, Takasawa N, Ishii T, Harigae H.
   The use of tacrolimus for recurrent lupus enteritis: a case report.
   J Med Case Rep. 2010 May 24;4:150. doi: 10.1186/1752-1947-4-150.
10. Yokoyama H, Yamamoto J, Tohmiya Y, Yamada MF, Ohguchi H, Ohnishi Y, Okitsu Y, Fukuhara N, Ohba-Ohtsuka R, Kohata K, Ishizawa K, Kameoka J, Harigae H.
    Allogeneic hematopoietic stem cell transplant following chemotherapy containing l-asparaginase as a promising treatment for patients with relapsed or refractory extranodal natural killer/T cell lymphoma, nasal type.
    Leuk Lymphoma. 2010 Aug;51(8):1509-12. doi: 10.3109/10428194.2010.487958.
11. Watanabe R, Shirai T, Tajima Y, Ohguchi H, Onishi Y, Fujii H, Takasawa N, Ishii T, Harigae H.
    Pregnancy-associated thrombotic thrombocytopenic purpura with anti-centromere antibody-positive Raynaud's syndrome.
    Intern Med. 2010;49(12):1229-32.
12. Watanabe R, Ishii T, Harigae H.
    Severe pharyngeal edema in systemic lupus erythematosus.
    Intern Med. 2010;49(12):1263-4.
13. Watanabe R, Ishii T, Harigae H.
    Churg-Strauss syndrome with exophthalmos and orbital bone destruction.
    Intern Med. 2010;49(14):1463-4.
14. Kohata K, Fujiwara T, Yamamoto J, Yamada M, Ishizawa K, Satoh K, Sekiguchi S, Kameoka J, Satomi S, Harigae H.
    [Severe autoimmune hemolytic anemia after ABO match living donor liver transplantation].
    Nihon Rinsho Meneki Gakkai Kaishi. 2010;33(1):20-3. Japanese.
15. Imoto A, Okada M, Okazaki T, Kitasato H, Harigae H, Takahashi S.
    Metallothionein-1 isoforms and vimentin are direct PU.1 downstream target genes in leukemia cells.
    J Biol Chem. 2010 Apr 2;285(14):10300-9. doi: 10.1074/jbc.M109.095810.
16. Matsuse D, Kitada M, Kohama M, Nishikawa K, Makinoshima H, Wakao S, Fujiyoshi Y, Heike T, Nakahata T, Akutsu H, Umezawa A, Harigae H, Kira J, Dezawa M.
    Human umbilical cord-derived mesenchymal stromal cells differentiate into functional Schwann cells that sustain peripheral nerve regeneration.
    J Neuropathol Exp Neurol. 2010 Sep;69(9):973-85. doi: 10.1097/NEN.0b013e3181eff6dc.
17. Nishiwaki S, Miyamura K, Kato C, Terakura S, Ohashi K, Sakamaki H, Nakao S, Harigae H, Kodera Y.
    Impact of post-transplant imatinib administration on Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Anticancer Res. 2010 Jun;30(6):2415-8.
18. Ohmachi K, Ando K, Ogura M, Uchida T, Itoh K, Kubota N, Ishizawa K, Yamamoto J, Watanabe T, Uike N, Choi I, Terui Y, Usuki K, Nagai H, Uoshima N, Tobinai K; Japanese Bendamustine Lymphoma Study Group.
    Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
    Cancer Sci. 2010 Sep;101(9):2059-64. doi: 10.1111/j.1349-7006.2010.01635.x.
19. Otomo T, Fuse N, Ishizawa K, Seimiya M, Shimura M, Ichinohasama R.
    Japanese case of follicular lymphoma of ocular adnexa diagnosed by clinicopathologic, immunohistochemical, and molecular genetic techniques.
    Clin Ophthalmol. 2010 Dec 1;4:1397-402. doi: 10.2147/OPTH.S15219.
20. Shichishima T, Ikeda K, Takahashi N, Kameoka J, Tajima K, Murai K, Tamai Y, Shichishima-Nakamura A, Akutsu K, Noji H, Okamoto M, Kimura H, Harigae H, Oyamada T, Kamesaki T, Takeishi Y, Sawada K.
    Low concentration of serum haptoglobin has impact on understanding complex pathophysiology in patients with acquired bone marrow failure syndromes.
    Int J Hematol. 2010 May;91(4):602-10. doi: 10.1007/s12185-010-0559-z.
21. Tahara T, Yamamoto M, Akagi R, Harigae H, Taketani S.
    The low expression allele (IVS3-48C) of the ferrochelatase gene leads to low enzyme activity associated with erythropoietic protoporphyria.
    Int J Hematol. 2010 Dec;92(5):769-71. doi: 10.1007/s12185-010-0725-3.
22. Tobinai K, Ogura M, Maruyama D, Uchida T, Uike N, Choi I, Ishizawa K, Itoh K, Ando K, Taniwaki M, Shimada N, Kobayashi K.
    Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma.
    Int J Hematol. 2010 Nov;92(4):563-70. doi: 10.1007/s12185-010-0707-5.

 

 

2009年

1. Abe M, Yokoyama H, Tohmiya Y, Okitsu Y, Ohguchi H, Kohata K, Yamamoto J, Onishi Y, Ishizawa K, Kameoka J, Harigae H.
   Plasma cell leukemia maintaining complete remission by syngeneic stem cell transplantation combined with low-dose thalidomide maintenance therapy.
   Intern Med. 2009;48(20):1833-5.
2. Hirabayashi Y, Ishii T, Harigae H.
   Clinical efficacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practice.
   Rheumatol Int. 2010 Jun;30(8):1041-8. doi: 10.1007/s00296-009-1095-0.
3. Ichikawa S, Kohata K, Okitsu Y, Suzuki M, Nakajima S, Yamada MF, Onishi Y, Yamamoto J, Suzuki S, Ishizawa K, Kameoka J, Harigae H.
   Acquired hemophilia A with sigmoid colon cancer: successful treatment with rituximab followed by sigmoidectomy.
   Int J Hematol. 2009 Jul;90(1):33-6. doi: 10.1007/s12185-009-0347-9.
4. Ishizawa K, Ogura M, Hamaguchi M, Hotta T, Ohnishi K, Sasaki T, Sakamaki H, Yokoyama H, Harigae H, Morishima Y.
   Safety and efficacy of rasburicase (SR29142) in a Japanese phase II study.
   Cancer Sci. 2009 Feb;100(2):357-62. doi: 10.1111/j.1349-7006.2008.01047.x.
5. Ohguchi H, Sugawara T, Harigae H.
   Thrombotic thrombocytopenic purpura complicated with hypereosinophilic syndrome.
   Intern Med. 2009;48(18):1687-90.
6. Ohguchi H, Sugawara T, Ishikawa I, Okuda M, Tomiya Y, Yamamoto J, Onishi Y, Fujiwara Yamada M, Ishizawa K, Kameoka J, Harigae H.
   A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: beta2-microglobulin associated with time to progression.
   Int J Hematol. 2009 Apr;89(3):342-7. doi: 10.1007/s12185-009-0279-4.
7. Shirai T, Takahashi R, Tajima Y, Kohata K, Yamamoto J, Fujii H, Takasawa N, Ishizawa K, Ichinohasama R, Ishii T, Harigae H.
   Peripheral T cell lymphoma with a high titer of proteinase-3-antineutrophil cytoplasmic antibodies that resembled Wegener's granulomatosis.
   Intern Med. 2009;48(23):2041-5.
8. Yamada MF, Miyamura K, Fujiwara T, Kohata K, Okitsu Y, Ohguchi H, Yamamoto J, Yokoyama H, Tomiya Y, Ishizawa K, Kameoka J, Harigae H.
   Myeloablative cord blood transplantation for adults with hematological malignancies using tacrolimus and short-term methotrexate for graft-versus-host disease prophylaxis: single-institution analysis.
   Transplant Proc. 2008 Dec;40(10):3637-42. doi: 10.1016/j.transproceed.2008.06.102.
9. Yokoyama H, Harigae H.
   [Management of anemia and bone marrow hypoplasia in the treatment of myeloid leukemia].
   Nihon Rinsho. 2009 Oct;67(10):1974-7. Review. Japanese.
10. Iseki Y, Imoto A, Okazaki T, Harigae H, Takahashi S.
    Identification of annexin 1 as a PU.1 target gene in leukemia cells.
    Leuk Res. 2009 Dec;33(12):1658-63. doi: 10.1016/j.leukres.2009.04.010.
11. Okuyama R, Shimada R, Kameoka J, Harigae H, Aiba S.
    Occurrence of poroid hidradenomas after haematopoietic stem cell transplantation.
    J Eur Acad Dermatol Venereol. 2009 Sep;23(9):1109-11. doi: 10.1111/j.1468-3083.2009.03110.x.
12. Tobinai K, Watanabe T, Ogura M, Morishima Y, Hotta T, Ishizawa K, Itoh K, Okamoto S, Taniwaki M, Tsukamoto N, Okumura H, Terauchi T, Nawano S, Matsusako M, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Hayashi M, Endo K.
    Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma.
    Cancer Sci. 2009 Jan;100(1):158-64. doi: 10.1111/j.1349-7006.2008.00999.x.
13. Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, Ishizawa K, Maseki N, Itoh K, Usui N, Wasada I, Kinoshita T, Ohshima K, Matsuno Y, Terauchi T, Nawano S, Ishikura S, Kagami Y, Hotta T, Oshimi K.
    Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211.
    J Clin Oncol. 2009 Nov 20;27(33):5594-600. doi: 10.1200/JCO.2009.23.8295.

 

 

2008年

1. Abe S, Kameoka J, Fujiwara M, Harigae H, Sasaki O, Miyamura K.
   Trisomies 4 and 10 in acute myeloid leukemia: report of a new case.
   Cancer Genet Cytogenet. 2008 Aug;185(1):55-6. doi: 10.1016/j.cancergencyto.2008.04.013.
2. Abe S, Ishikawa I, Harigae H, Sugawara T.
   A new complex translocation t(5;17;15)(q11;q21;q22) in acute promyelocytic leukemia.
   Cancer Genet Cytogenet. 2008 Jul;184(1):44-7. doi: 10.1016/j.cancergencyto.2008.03.006.
3. Ohguchi H, Tanaka T, Uchida A, Magoori K, Kudo H, Kim I, Daigo K, Sakakibara I, Okamura M, Harigae H, Sasaki T, Osborne TF, Gonzalez FJ, Hamakubo T, Kodama T, Sakai J.
   Hepatocyte nuclear factor 4alpha contributes to thyroid hormone homeostasis by cooperatively regulating the type 1 iodothyronine deiodinase gene with GATA4 and Kruppel-like transcription factor 9.
   Mol Cell Biol. 2008 Jun;28(12):3917-31. doi: 10.1128/MCB.02154-07.
4. Yamada MF, Fujiwara T, Ishikawa I, Kohata K, Katoh C, Miyamura K, Harigae H.
   Interlaboratory comparison of quantitative RT-PCR based detection for minimal residual disease in leukemias: a standardization approach in Japan.
   Tohoku J Exp Med. 2008 Feb;214(2):97-104.
5. Harigae H.
   [Anemia and iron metabolism].
   Rinsho Ketsueki. 2008 Oct;49(10):1285-90. Review. Japanese.
6. Oka Y, Kameoka J, Hirabayashi Y, Takahashi R, Ishii T, Sasaki T, Harigae H.
   Reversible bone marrow dysplasia in patients with systemic lupus erythematosus.
   Intern Med. 2008;47(8):737-42. Epub 2008 Apr 16.
7. Suzuki N, Katsusihma H, Takeuchi K, Nakamura S, Ishizawa K, Ishii S, Moriya T, DeCoteau JF, Miura I, Ichinohasama R.
   Cytogenetic abnormality 46,XX,add(21)(q11.2) in a patient with follicular dendritic cell sarcoma.
   Cancer Genet Cytogenet. 2008 Oct;186(1):54-7. doi: 10.1016/j.cancergencyto.2008.06.002.
8. Tobinai K, Kameoka J, Uike N, Shinagawa A, Takita M.
   [Diagnosis and treatment of malignant lymphoma: discussion].
   Nihon Naika Gakkai Zasshi. 2008 Jul 10;97(7):1637-54. Japanese.
9. Tsuchiyama K, Okuyama R, Ogawa E, Inoue A, Ishizawa K, Harigae H, Aiba S.
   Ecthyma gangrenosum with Citrobacter freundii infection.
   J Eur Acad Dermatol Venereol. 2009 Jun;23(6):709-10. doi: 10.1111/j.1468-3083.2008.03000.x.